fluorouracil has been researched along with Innate Inflammatory Response in 137 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of the study was to assess the impact of an eicosapentanoic acid-containing protein and energy dense oral nutritional supplement (EPA-ONS) on nutritional and inflammatory status, quality of life (QOL), plasma phospholipids (PPL) and cytokine profile, tolerance of irinotecan-containing chemotherapy and EPA-ONS in patients with advanced colorectal cancer (CRC) receiving chemotherapy." | 9.12 | Nutrition intervention using an eicosapentaenoic acid (EPA)-containing supplement in patients with advanced colorectal cancer. Effects on nutritional and inflammatory status: a phase II trial. ( Beale, PJ; Childs, A; Clarke, SJ; Read, JA; Smith, N; Volker, DH, 2007) |
| "5-Fluorouracil (5-FU) is a common anti-tumor drug, but there is no effective treatment for its side effect, intestinal mucositis." | 8.31 | Short-Chain Fatty Acids Attenuate 5-Fluorouracil-Induced THP-1 Cell Inflammation through Inhibiting NF-κB/NLRP3 Signaling via Glycerolphospholipid and Sphingolipid Metabolism. ( Gong, W; Wang, C; Wang, D; Wu, L; Xi, Y; Yang, C; Zhang, Y, 2023) |
| "Cancer patients treated with capecitabine and oxaliplatin (XELOX) often develop hand-foot syndrome (HFS) or palmar-plantar erythrodysesthesia." | 8.12 | Genetic variation in ST6GAL1 is a determinant of capecitabine and oxaliplatin induced hand-foot syndrome. ( Al-Tassan, NA; Cheadle, JP; Escott-Price, V; Houlston, RS; Kaplan, R; Kerr, DJ; Kerr, R; Madi, A; Maughan, TS; Palles, C; Watts, K; Wills, C, 2022) |
| "Intestinal mucositis (IM) is a common side effect of 5-fluorouracil (5-FU)-based chemotherapy, which negatively impacts therapeutic outcomes and delays subsequent cycles of chemotherapy resulting in dose reductions and treatment discontinuation." | 8.02 | Losartan improves intestinal mucositis induced by 5-fluorouracil in mice. ( Barra, PB; da Silva Martins Rebouças, C; de Araújo, AA; de Carvalho Leitão, RF; de Castro Brito, GA; de Medeiros, CACX; de Sales Mota, PCM; Figueiredo, JG; Guerra, GCB; Marques, VB; Oliveira, MMB; Ribeiro, SB, 2021) |
| "oil in treating 5-fluorouracil (5-FU)-induced intestinal mucositis have not yet been reported." | 7.96 | Patchouli oil ameliorates 5-fluorouracil-induced intestinal mucositis in rats via protecting intestinal barrier and regulating water transport. ( Ai, G; Chen, L; Gan, Y; Huang, Q; Huang, X; Li, M; Liu, Y; Luo, H; Su, Z; Wu, J; Wu, X; Xu, N, 2020) |
| " Here, we evaluated the anti-inflammatory Trimethylglycine and the Signal transducer and activator of transcription (STAT6) inhibitor AS1517499, as possible adjuvants to 5-FU in already established cancers, using a model of colitis-associated colon cancer (CAC)." | 7.96 | Use of STAT6 Phosphorylation Inhibitor and Trimethylglycine as New Adjuvant Therapies for 5-Fluorouracil in Colitis-Associated Tumorigenesis. ( Beristain-Terrazas, DL; Callejas, BE; Chirino, YI; Delgado-Buenrostro, NL; García-Castillo, V; Gutierrez-Cirlos, EB; León-Cabrera, SA; Mendoza-Rodríguez, MG; Meraz-Ríos, MA; Pérez-Plasencia, C; Rodríguez-Sosa, M; Sánchez-Barrera, CÁ; Terrazas, LI; Vaca-Paniagua, F, 2020) |
| " We sought to characterize the effects of 5 fluorouracil (5FU) chemotherapy on colon inflammation and functional measures in colorectal cancer (CRC) and to further determine whether gut microbiota can influence this response." | 7.91 | Impact of 5 fluorouracil chemotherapy on gut inflammation, functional parameters, and gut microbiota. ( Bader, JE; Carson, JA; Carson, M; Chatzistamou, I; Enos, RT; Kubinak, JL; Murphy, EA; Nagarkatti, M; Pena, MM; Sougiannis, AT; VanderVeen, BN; Velazquez, KT; Walla, M, 2019) |
| "To study the efficacy of microneedling with 5-flurouracil vs its efficacy with tacrolimus in the treatment of vitiligo." | 7.88 | Comparison between the efficacy of microneedling combined with 5-fluorouracil vs microneedling with tacrolimus in the treatment of vitiligo. ( Al-Saeid, H; Elgarhy, L; Ibrahim, Z; Mina, M, 2018) |
| " 5-Fluorouracil (5-FU), widely used for cancer chemotherapy, is known to frequently induce intestinal mucositis accompanied by severe diarrhoea." | 7.85 | Probiotic Bifidobacterium bifidum G9-1 attenuates 5-fluorouracil-induced intestinal mucositis in mice via suppression of dysbiosis-related secondary inflammatory responses. ( Amagase, K; Hamouda, N; Kano, Y; Kato, S; Matsumoto, K; Oikawa, Y; Shimakawa, M; Tanaka, Y, 2017) |
| "Disturbed homeostasis of gut microbiota has been suggested to be closely associated with 5-fluorouracil (5-Fu) induced mucositis." | 7.85 | Alteration of Gut Microbiota and Inflammatory Cytokine/Chemokine Profiles in 5-Fluorouracil Induced Intestinal Mucositis. ( Huang, F; Li, HL; Lu, L; Qin, LY; Qiu, SP; Shi, HL; Wang, P; Wang, XS; Wu, H; Wu, XJ; Zhang, BB, 2017) |
| "This study aimed to assess the effect of multiple sessions of a low-level laser therapy (LLLT) adjuvant to scaling and root planing (SRP) on the treatment of experimental periodontitis (EP) in rats treated with 5-fluorouracil (5-FU)." | 7.83 | Effect of low-level laser therapy as an adjuvant in the treatment of periodontitis induced in rats subjected to 5-fluorouracil chemotherapy. ( Assem, NZ; Duque, C; Ervolino, E; Ferro-Alves, ML; Garcia, VG; Longo, M; Louzada, LM; Theodoro, LH, 2016) |
| "These results demonstrate the beneficial effect of quercetin on improving recovery of voluntary physical activity following 5-FU treatment, which may be linked to a decrease in inflammation and anemia." | 7.80 | Dietary quercetin reduces chemotherapy-induced fatigue in mice. ( Davis, JM; Mahoney, SE; McClellan, JL; Murphy, EA; Pena, MM, 2014) |
| "Preclinical in vitro and in vivo studies have demonstrated synergistic interactions between 5-fluorouracil (5-FU) and type I and II IFNs against human colorectal cancer cells." | 7.72 | Combined 5-fluorouracil/systemic interferon-beta gene therapy results in long-term survival in mice with established colorectal liver metastases. ( Barsoum, J; Choi, EA; Fraker, DL; Lei, H; Maron, DJ; Mick, R; Spitz, FR; Wilson, JM; Yu, QC, 2004) |
| "We reviewed the records of 12 eyes of ten adult patients with inflammatory glaucoma who underwent trabeculectomy with the adjuvant use of 5-fluorouracil between January 1986 and January 1989." | 7.68 | Trabeculectomy with 5-fluorouracil for adult inflammatory glaucoma. ( Jabs, DA; Jampel, HD; Quigley, HA, 1990) |
| "Rupatadine pretreatment reduced the previously mentioned parameters, preserved a nearly normal intestinal mucosa picture with replenished GSH and elevated IL-10." | 5.72 | Rupatadine protects the intestinal mucosa from injury by 5-flurouracil via modulation of inflammation, apoptosis and intestinal permeability. ( Mohamed, MZ; Mohammed, HH, 2022) |
| "Metformin has anti-inflammatory effects, but its role in the mechanism of treatment in intestinal injury caused by 5-Fu remains unclear." | 5.72 | Metformin ameliorates 5-fluorouracil-induced intestinalinjury by inhibiting cellular senescence, inflammation, and oxidative stress. ( Chen, J; Dai, Q; Ge, Y; He, S; Shi, YL; Vashisth, MK; Wang, XB; Xia, J, 2022) |
| "Patchouli alcohol (PA) is an active compound extracted from Pogostemon cablin, and has potent gastrointestinal protective effect." | 5.56 | Patchouli alcohol attenuates 5-fluorouracil-induced intestinal mucositis via TLR2/MyD88/NF-kB pathway and regulation of microbiota. ( Chen, L; Gan, Y; Li, M; Liang, J; Lin, Z; Liu, Y; Luo, H; Su, Z; Wu, J; Wu, Q; Wu, X; Xu, N; Zhuo, J, 2020) |
| "Zinc sulfate has a beneficial role, decreasing the severity of gut mucosal injuries induced by 5-FU in Wistar rats." | 5.56 | Beneficial effect of oral administration of zinc sulfate on 5-fluorouracil-induced gastrointestinal mucositis in rats. ( Berce, C; Ciobanu, L; Meșter, A; Onica, S; Tanțău, M; Taulescu, M; Tefas, C; Toma, C, 2020) |
| "Mucositis was induced by intraperitoneal injection of 300 mg/kg 5-FU." | 5.48 | Conjugated linoleic acid prevents damage caused by intestinal mucositis induced by 5-fluorouracil in an experimental model. ( Alvarez Leite, JI; Antunes Fernandes, SO; Cardoso, VN; Cassali, GD; da Gama, MAS; de Barros, PAV; de Sales E Souza, ÉL; de Vasconcelos Generoso, S; Dos Reis, DC; Dos Santos Martins, F; Lacerda Leocádio, PC; Mendes Miranda, SE; Rabelo Andrade, ME, 2018) |
| "Chemotherapy-associated steatohepatitis is attracting increasing attention because it heralds an increased risk of morbidity and mortality in patients undergoing surgery because of liver metastases." | 5.46 | Analysis of molecular mechanisms of 5-fluorouracil-induced steatosis and inflammation in vitro and in mice. ( Bosserhoff, AK; Freese, K; Hellerbrand, C; Kuecuekoktay, FS; Mahli, A; Müller, M; Schiergens, TS; Sommer, J; Teufel, A; Thasler, WE, 2017) |
| "Mucositis was induced on day 5 by 5-FU injection (150mg/kg i." | 5.35 | Lyprinol only partially improves indicators of small intestinal integrity in a rat model of 5-fluorouracil-induced mucositis. ( Butler, RN; Geier, MS; Howarth, GS; Smith, CL; Tooley, KL; Torres, DM, 2008) |
| "She was diagnosed as inflammatory breast cancer clinically and invasive ductal carcinoma with lymphatic invasion pathologically." | 5.34 | [A case of inflammatory breast cancer achieving pathological complete response by primary systemic therapy with CEF (cyclophosphamide, epirubicin, 5-fluorouracil) followed by docetaxel]. ( Ando, M; Matsuyama, Y; Ooi, Y; Rai, Y; Sagara, Y; Takahama, T; Tamada, S; Tsuchimochi, S, 2007) |
| "Inflammation of actinic keratoses (AK) was originally described with systemic 5-fluorouracil, and led to the development of topical fluorouracil." | 5.22 | Inflamed actinic keratoses as a biomarker in repositioning of chemotherapeutics: a systematic review and meta-analysis. ( Jemec, GBE; Peteln, I; Šuler Baglama, Š, 2022) |
| "The use of bevacizumab in combination with fluoropyrimidine-containing chemotherapy is a well-established first-line and second-line treatment for patients with metastatic colorectal cancer (mCRC)." | 5.17 | An Australian translational study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (Avastin™) [ASCENT]. ( Burge, M; Clarke, S; Cordwell, C; Gibbs, P; Reece, W; Tebbutt, N, 2013) |
| "The aim of the study was to assess the impact of an eicosapentanoic acid-containing protein and energy dense oral nutritional supplement (EPA-ONS) on nutritional and inflammatory status, quality of life (QOL), plasma phospholipids (PPL) and cytokine profile, tolerance of irinotecan-containing chemotherapy and EPA-ONS in patients with advanced colorectal cancer (CRC) receiving chemotherapy." | 5.12 | Nutrition intervention using an eicosapentaenoic acid (EPA)-containing supplement in patients with advanced colorectal cancer. Effects on nutritional and inflammatory status: a phase II trial. ( Beale, PJ; Childs, A; Clarke, SJ; Read, JA; Smith, N; Volker, DH, 2007) |
| "5-Fluorouracil (5-FU) is a common anti-tumor drug, but there is no effective treatment for its side effect, intestinal mucositis." | 4.31 | Short-Chain Fatty Acids Attenuate 5-Fluorouracil-Induced THP-1 Cell Inflammation through Inhibiting NF-κB/NLRP3 Signaling via Glycerolphospholipid and Sphingolipid Metabolism. ( Gong, W; Wang, C; Wang, D; Wu, L; Xi, Y; Yang, C; Zhang, Y, 2023) |
| "Intestinal mucositis is characterized by inflammation and ulceration of the mucosa that affects the gastrointestinal tract and is associated with administering some drugs, such as 5- Fluorouracil (5-FU), conventional chemotherapy used in clinics for cancer therapy." | 4.31 | Protective Effect of ( Araújo, DD; da Silva Souza, B; de Andrade, GL; de Freitas, CDT; de Oliveira, JS, 2023) |
| "5-Fluorouracil (5-FU) is a used chemotherapy drug for cancer, and its main side effect is intestinal mucositis which causes chemotherapy to fail." | 4.12 | Three important short-chain fatty acids (SCFAs) attenuate the inflammatory response induced by 5-FU and maintain the integrity of intestinal mucosal tight junction. ( Chang, S; Jie, M; Liang, W; Long-Kun, D; Man, Y; Min, Z; Shuang-Yu, L; Wen, S; Xin, Q; Yue, X, 2022) |
| "Cancer patients treated with capecitabine and oxaliplatin (XELOX) often develop hand-foot syndrome (HFS) or palmar-plantar erythrodysesthesia." | 4.12 | Genetic variation in ST6GAL1 is a determinant of capecitabine and oxaliplatin induced hand-foot syndrome. ( Al-Tassan, NA; Cheadle, JP; Escott-Price, V; Houlston, RS; Kaplan, R; Kerr, DJ; Kerr, R; Madi, A; Maughan, TS; Palles, C; Watts, K; Wills, C, 2022) |
| "In this study, the oral mucosa of mice was burned with 90% phenol and intraperitoneal injection of 5-fluorouracil to establish the model of stomatitis mice." | 4.12 | Dual roles of ANGPTL4 in multiple inflammatory responses in stomatitis mice. ( Tian, MM; Wang, YS; Xiao, HB, 2022) |
| "Intestinal mucositis (IM) is a common side effect of 5-fluorouracil (5-FU)-based chemotherapy, which negatively impacts therapeutic outcomes and delays subsequent cycles of chemotherapy resulting in dose reductions and treatment discontinuation." | 4.02 | Losartan improves intestinal mucositis induced by 5-fluorouracil in mice. ( Barra, PB; da Silva Martins Rebouças, C; de Araújo, AA; de Carvalho Leitão, RF; de Castro Brito, GA; de Medeiros, CACX; de Sales Mota, PCM; Figueiredo, JG; Guerra, GCB; Marques, VB; Oliveira, MMB; Ribeiro, SB, 2021) |
| " Intestinal mucositis characterized by intense inflammation is the main side effect associated with 5-fluorouracil (5-FU) treatment." | 3.96 | Modulation of 5-fluorouracil activation of toll-like/MyD88/NF-κB/MAPK pathway by Saccharomyces boulardii CNCM I-745 probiotic. ( Barbosa, ALR; Czerucka, D; Franco, AX; Justino, PFC; Monteiro, CES; Pontier-Bres, R; Soares, PMG; Souza, MHLP, 2020) |
| "oil in treating 5-fluorouracil (5-FU)-induced intestinal mucositis have not yet been reported." | 3.96 | Patchouli oil ameliorates 5-fluorouracil-induced intestinal mucositis in rats via protecting intestinal barrier and regulating water transport. ( Ai, G; Chen, L; Gan, Y; Huang, Q; Huang, X; Li, M; Liu, Y; Luo, H; Su, Z; Wu, J; Wu, X; Xu, N, 2020) |
| " Here, we evaluated the anti-inflammatory Trimethylglycine and the Signal transducer and activator of transcription (STAT6) inhibitor AS1517499, as possible adjuvants to 5-FU in already established cancers, using a model of colitis-associated colon cancer (CAC)." | 3.96 | Use of STAT6 Phosphorylation Inhibitor and Trimethylglycine as New Adjuvant Therapies for 5-Fluorouracil in Colitis-Associated Tumorigenesis. ( Beristain-Terrazas, DL; Callejas, BE; Chirino, YI; Delgado-Buenrostro, NL; García-Castillo, V; Gutierrez-Cirlos, EB; León-Cabrera, SA; Mendoza-Rodríguez, MG; Meraz-Ríos, MA; Pérez-Plasencia, C; Rodríguez-Sosa, M; Sánchez-Barrera, CÁ; Terrazas, LI; Vaca-Paniagua, F, 2020) |
| " We sought to characterize the effects of 5 fluorouracil (5FU) chemotherapy on colon inflammation and functional measures in colorectal cancer (CRC) and to further determine whether gut microbiota can influence this response." | 3.91 | Impact of 5 fluorouracil chemotherapy on gut inflammation, functional parameters, and gut microbiota. ( Bader, JE; Carson, JA; Carson, M; Chatzistamou, I; Enos, RT; Kubinak, JL; Murphy, EA; Nagarkatti, M; Pena, MM; Sougiannis, AT; VanderVeen, BN; Velazquez, KT; Walla, M, 2019) |
| "To study the efficacy of microneedling with 5-flurouracil vs its efficacy with tacrolimus in the treatment of vitiligo." | 3.88 | Comparison between the efficacy of microneedling combined with 5-fluorouracil vs microneedling with tacrolimus in the treatment of vitiligo. ( Al-Saeid, H; Elgarhy, L; Ibrahim, Z; Mina, M, 2018) |
| "Mucositis is an inflammatory condition of the gut, caused by an adverse effect of chemotherapy drugs, such as 5-fluorouracil (5-FU)." | 3.88 | Gut microbiome modulation during treatment of mucositis with the dairy bacterium Lactococcus lactis and recombinant strain secreting human antimicrobial PAP. ( Aguiar, E; Azevedo, V; Bermudez, L; Carvalho, R; Chatel, JM; Dorella, F; Fernandes, G; Figueiredo, H; Goes-Neto, A; Langella, P; Pereira, FL; Vaz, A, 2018) |
| "5-Fluorouracil (5-FU) is the chemotherapeutic agent of first choice for the treatment ofcolorectal cancer, however, treatment-related liver toxicity remains a major concern." | 3.85 | Hepatoprotective Effect of Carboxymethyl Pachyman in Fluorouracil-Treated CT26-Bearing Mice. ( Gao, L; Huo, X; Li, C; Sun, G; Wang, C, 2017) |
| " 5-Fluorouracil (5-FU), widely used for cancer chemotherapy, is known to frequently induce intestinal mucositis accompanied by severe diarrhoea." | 3.85 | Probiotic Bifidobacterium bifidum G9-1 attenuates 5-fluorouracil-induced intestinal mucositis in mice via suppression of dysbiosis-related secondary inflammatory responses. ( Amagase, K; Hamouda, N; Kano, Y; Kato, S; Matsumoto, K; Oikawa, Y; Shimakawa, M; Tanaka, Y, 2017) |
| "Disturbed homeostasis of gut microbiota has been suggested to be closely associated with 5-fluorouracil (5-Fu) induced mucositis." | 3.85 | Alteration of Gut Microbiota and Inflammatory Cytokine/Chemokine Profiles in 5-Fluorouracil Induced Intestinal Mucositis. ( Huang, F; Li, HL; Lu, L; Qin, LY; Qiu, SP; Shi, HL; Wang, P; Wang, XS; Wu, H; Wu, XJ; Zhang, BB, 2017) |
| " Transplantation of bone marrow hematopoietic stem and progenitor cells from diabetic C57Bl/6 donor mice to recipient CBA mice with 5-fluorouracilinduced leukopenia accelerated regeneration of granulocytopoiesis in recipient mice." | 3.83 | Role of Hematopoietic Stem Cells in Inflammation of the Pancreas during Diabetes Mellitus. ( Choinzonov, EL; Dygai, AM; Ellinidi, VN; Ermakova, NN; Ermolaeva, LA; Goldberg, VE; Kravtsov, VY; Krupin, VA; Pershina, OV; Reikhart, DV; Skurikhin, EG; Stakheeva, MN, 2016) |
| "This study aimed to assess the effect of multiple sessions of a low-level laser therapy (LLLT) adjuvant to scaling and root planing (SRP) on the treatment of experimental periodontitis (EP) in rats treated with 5-fluorouracil (5-FU)." | 3.83 | Effect of low-level laser therapy as an adjuvant in the treatment of periodontitis induced in rats subjected to 5-fluorouracil chemotherapy. ( Assem, NZ; Duque, C; Ervolino, E; Ferro-Alves, ML; Garcia, VG; Longo, M; Louzada, LM; Theodoro, LH, 2016) |
| "These results demonstrate the beneficial effect of quercetin on improving recovery of voluntary physical activity following 5-FU treatment, which may be linked to a decrease in inflammation and anemia." | 3.80 | Dietary quercetin reduces chemotherapy-induced fatigue in mice. ( Davis, JM; Mahoney, SE; McClellan, JL; Murphy, EA; Pena, MM, 2014) |
| "We report the case of a 35-year-old pregnant woman with inflammatory breast carcinoma initially treated with 5-fluorouracil/doxorubicin/cyclophosphamide beginning her 13th week of pregnancy." | 3.73 | Docetaxel administered during pregnancy for inflammatory breast carcinoma. ( Aramendía, JM; Fernández-Hidalgo, O; García-Manero, M; López, G; Nieto, Y; Santisteban, M, 2006) |
| "Preclinical in vitro and in vivo studies have demonstrated synergistic interactions between 5-fluorouracil (5-FU) and type I and II IFNs against human colorectal cancer cells." | 3.72 | Combined 5-fluorouracil/systemic interferon-beta gene therapy results in long-term survival in mice with established colorectal liver metastases. ( Barsoum, J; Choi, EA; Fraker, DL; Lei, H; Maron, DJ; Mick, R; Spitz, FR; Wilson, JM; Yu, QC, 2004) |
| "We studied longitudinally inflammatory reactions and serum C-reactive protein (S-CRP) levels in 52 colorectal cancer patients treated with a median of six 3-weekly cycles of raltitrexed 1." | 3.71 | Raltitrexed treatment promotes systemic inflammatory reaction in patients with colorectal carcinoma. ( Elomaa, I; Joensuu, H; Orpana, A; Osterlund, P; Repo, H, 2002) |
| "We reviewed the records of 12 eyes of ten adult patients with inflammatory glaucoma who underwent trabeculectomy with the adjuvant use of 5-fluorouracil between January 1986 and January 1989." | 3.68 | Trabeculectomy with 5-fluorouracil for adult inflammatory glaucoma. ( Jabs, DA; Jampel, HD; Quigley, HA, 1990) |
| "A cerebral demyelinating disease developed in 3 patients during adjuvant therapy with 5-fluorouracil and levamisole for adenocarcinoma of the colon." | 3.68 | Multifocal inflammatory leukoencephalopathy with 5-fluorouracil and levamisole. ( Forsyth, PA; Hook, CC; Kimmel, DW; Kvols, LK; Moertel, CG; Rodriguez, M; Rubin, J; Scheithauer, BW, 1992) |
| "The antimetabolite 5-fluorouracil (5-FU) was used as adjunctive treatment in glaucomatous eyes with poor prognoses undergoing filtering surgery." | 3.67 | Adjusting the dose of 5-fluorouracil after filtration surgery to minimize side effects. ( Weinreb, RN, 1987) |
| " There were 17 recorded adverse events in total." | 3.01 | S-1 and 5-Fluorouracil-related adverse events in patients with advanced gastric cancer: A meta-analysis. ( Chu, T; Hu, Q; Ke, J; Xu, J; Zhang, Z, 2023) |
| "In patients with metastatic colorectal cancer that have previously received treatment with 5-FU based chemotherapy, treatment with SIR-spheres has demonstrated encouraging activity." | 2.71 | A prospective evaluation of treatment with Selective Internal Radiation Therapy (SIR-spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy. ( Bailey, W; Dowling, R; Gibbs, P; Liechtenstein, M; Lim, L; Little, A; Shapiro, JD; Smith, D; Yip, D, 2005) |
| "The presence of inflammatory breast cancer lowers the median survival time from 6." | 2.71 | Health-related quality of life parameters as prognostic factors in a nonmetastatic breast cancer population: an international multicenter study. ( Bottomley, A; Coens, C; Cufer, T; de Haes, H; Dyczka, J; Efficace, F; Lichinitser, M; Piccart, MJ; Shepherd, L; Sprangers, MA; Therasse, P; van Steen, K; Welnicka-Jaskiewicz, M, 2004) |
| "Hypertrophic scars and keloids may complicate wound healing secondary to trauma or surgery." | 2.69 | Treatment of inflamed hypertrophic scars using intralesional 5-FU. ( Fitzpatrick, RE, 1999) |
| "Gastrointestinal mucositis is a common and debilitating side-effect of anticancer therapy contributing to dose reductions, delays and cessation of treatment, greatly impacting clinical outcomes." | 2.66 | Impact of chemotherapy-induced enteric nervous system toxicity on gastrointestinal mucositis. ( Al Thaalibi, M; McQuade, RM; Nurgali, K, 2020) |
| "Pretreatment with allopurinol did not reduce the toxicity of 5-FU administered as an intravenous bolus." | 2.65 | Effect of allopurinol on the toxicity of high-dose 5-fluorouracil administered by intermittent bolus injection. ( Howell, SB; Pfeifle, CE; Wung, WE, 1983) |
| "Chemotherapy-induced diarrhea (CID) is a common and often severe side effect experienced by colorectal cancer (CRC) patients during their treatment." | 2.50 | Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation. ( Doherty, GA; Lee, CS; Ryan, EJ, 2014) |
| "Patients with advanced pancreatic cancer treated with FOLFIRINOX chemotherapy alone or with FOLFIRINOX chemotherapy followed by stereotactic body radiotherapy between 2015 and 2021 in 2 tertiary referral centers were included." | 1.91 | Increasing Systemic Immune-inflammation Index During Treatment in Patients With Advanced Pancreatic Cancer is Associated With Poor Survival: A Retrospective, Multicenter, Cohort Study. ( Aziz, MH; Bonsing, BA; Groot Koerkamp, B; Homs, MYV; Luelmo, SAC; Michiels, N; Mieog, JSD; Papageorgiou, G; van 't Land, FR; van Eijck, CHJ, 2023) |
| "Metformin has anti-inflammatory effects, but its role in the mechanism of treatment in intestinal injury caused by 5-Fu remains unclear." | 1.72 | Metformin ameliorates 5-fluorouracil-induced intestinalinjury by inhibiting cellular senescence, inflammation, and oxidative stress. ( Chen, J; Dai, Q; Ge, Y; He, S; Shi, YL; Vashisth, MK; Wang, XB; Xia, J, 2022) |
| " Therefore, this study determined whether C3G alone or C3G combined with 5-fluorouracil (5-FU) inhibits human lung LCC." | 1.72 | The anticancer effects of cyanidin 3-O-glucoside combined with 5-fluorouracil on lung large-cell carcinoma in nude mice. ( Chang, GR; Liao, HJ; Lin, CF; Lin, TC; Liu, YW; Wu, CF; Wu, CY, 2022) |
| "Rupatadine pretreatment reduced the previously mentioned parameters, preserved a nearly normal intestinal mucosa picture with replenished GSH and elevated IL-10." | 1.72 | Rupatadine protects the intestinal mucosa from injury by 5-flurouracil via modulation of inflammation, apoptosis and intestinal permeability. ( Mohamed, MZ; Mohammed, HH, 2022) |
| "Zotarolimus is a semi-synthetic derivative of rapamycin and a novel immunosuppressive agent used to prevent graft rejection." | 1.62 | The Anti-Cancer Effects of a Zotarolimus and 5-Fluorouracil Combination Treatment on A549 Cell-Derived Tumors in BALB/c Nude Mice. ( Chang, GR; Chiou, RY; Hou, PH; Kuo, CY; Lin, CF; Lin, TC; Wang, CM; Wu, CF; Wu, CY; Yang, WC, 2021) |
| "Patchouli alcohol (PA) is an active compound extracted from Pogostemon cablin, and has potent gastrointestinal protective effect." | 1.56 | Patchouli alcohol attenuates 5-fluorouracil-induced intestinal mucositis via TLR2/MyD88/NF-kB pathway and regulation of microbiota. ( Chen, L; Gan, Y; Li, M; Liang, J; Lin, Z; Liu, Y; Luo, H; Su, Z; Wu, J; Wu, Q; Wu, X; Xu, N; Zhuo, J, 2020) |
| "Zinc sulfate has a beneficial role, decreasing the severity of gut mucosal injuries induced by 5-FU in Wistar rats." | 1.56 | Beneficial effect of oral administration of zinc sulfate on 5-fluorouracil-induced gastrointestinal mucositis in rats. ( Berce, C; Ciobanu, L; Meșter, A; Onica, S; Tanțău, M; Taulescu, M; Tefas, C; Toma, C, 2020) |
| " The author here is proposing to test 5-FU in combination with a number of deoxynucleosides on animal models infected with this Covid-19." | 1.56 | 5-Fluorouracil in combination with deoxyribonucleosides and deoxyribose as possible therapeutic options for the Coronavirus, COVID-19 infection. ( Ahmad, SI, 2020) |
| "Patients with stage III colon cancer homogeneously treated with surgery followed by FOLFOX chemotherapy between Jan 2007 and Aug 2013 were included retrospectively." | 1.51 | Clinical significance of tumor-infiltrating lymphocytes and neutrophil-to-lymphocyte ratio in patients with stage III colon cancer who underwent surgery followed by FOLFOX chemotherapy. ( Baik, SH; Cha, YJ; Kang, J; Lee, KY; Park, EJ, 2019) |
| "Actinic keratoses (AKs) and squamous cell carcinoma in situ (SCCIS) are precursor lesions for cutaneous squamous cell carcinoma (cSCC), the second most common form of cancer." | 1.51 | Topical kinase inhibitors induce regression of cutaneous squamous cell carcinoma. ( Beer, J; D'Armas, S; Daifallah, AEM; Dentchev, T; Farag, AM; Hahn, J; Lee, V; Marshall, C; Sabry, HH; Seykora, F; Seykora, JT; Shankar, S; Yang, X, 2019) |
| "Mucositis was induced by intraperitoneal injection of 300 mg/kg 5-FU." | 1.48 | Conjugated linoleic acid prevents damage caused by intestinal mucositis induced by 5-fluorouracil in an experimental model. ( Alvarez Leite, JI; Antunes Fernandes, SO; Cardoso, VN; Cassali, GD; da Gama, MAS; de Barros, PAV; de Sales E Souza, ÉL; de Vasconcelos Generoso, S; Dos Reis, DC; Dos Santos Martins, F; Lacerda Leocádio, PC; Mendes Miranda, SE; Rabelo Andrade, ME, 2018) |
| "Cetuximab has activity against colorectal cancers." | 1.46 | Cetuximab strongly enhances immune cell infiltration into liver metastatic sites in colorectal cancer. ( Hazama, S; Iida, M; Inoue, Y; Kanekiyo, S; Nagano, H; Sakamoto, K; Suzuki, N; Takeda, S; Tokuhisa, Y; Tokumitsu, Y; Tomochika, S; Tsunedomi, R; Ueno, T; Yoshino, S, 2017) |
| "Chemotherapy-associated steatohepatitis is attracting increasing attention because it heralds an increased risk of morbidity and mortality in patients undergoing surgery because of liver metastases." | 1.46 | Analysis of molecular mechanisms of 5-fluorouracil-induced steatosis and inflammation in vitro and in mice. ( Bosserhoff, AK; Freese, K; Hellerbrand, C; Kuecuekoktay, FS; Mahli, A; Müller, M; Schiergens, TS; Sommer, J; Teufel, A; Thasler, WE, 2017) |
| " Here, we investigated whether the IMD in combination with chemotherapy could prevent cancer cachexia in colon 26 tumor-bearing mice." | 1.42 | An Immune-Modulating Diet in Combination with Chemotherapy Prevents Cancer Cachexia by Attenuating Systemic Inflammation in Colon 26 Tumor-Bearing Mice. ( Nakamura, K; Sasayama, A; Takahashi, T; Yamaji, T, 2015) |
| "Mucositis was then induced in the same animals by intraperitoneal injection of 5-fluorouracil (150 mg/kg) and burrowing behaviour recorded over three consecutive days." | 1.42 | The assessment of general well-being using spontaneous burrowing behaviour in a short-term model of chemotherapy-induced mucositis in the rat. ( Howarth, GS; Lymn, KA; Nicholson, A; Whittaker, AL, 2015) |
| "FuOx-resistant (chemoresistant; CR) colon cancer cells, highly enriched in CSCs, were used for this study." | 1.40 | Omega-3 fatty acid is a potential preventive agent for recurrent colon cancer. ( Banerjee, S; Dyson, G; Farhana, L; Levi, E; Maddipati, KR; Majumdar, AP; Nangia-Makker, P; Patel, A; Rajendra, SG; Vasudevan, A; Woods, J; Yu, Y, 2014) |
| "Oral mucositis was induced in male hamsters by two intraperitoneal administrations of 5-FU on the first and second days of the experiment (60 and 40 mg/kg, respectively) followed by mechanical trauma on the fourth day." | 1.40 | S-nitrosoglutathione accelerates recovery from 5-fluorouracil-induced oral mucositis. ( Baldim, V; Braga, CM; Brito, GA; Cavalcante, MM; Colombo, AP; de Oliveira, MG; Holanda-Afonso, RC; Leitão, RF; Moura-Neto, V; Ribeiro, RA; Silva-Boghossian, CM; Skeff, MA, 2014) |
| "5-Fluorouracil (5-FU) was used as a model drug, and hydroxyapatite (HA) was incorporated as a release modifier." | 1.36 | In vitro / in vivo evaluation of NCDS-micro-fabricated biodegradable implant. ( Ahn, SH; Chi, SC; Danh, SD; Park, CW; Park, ES; Park, SH; Rhee, YS, 2010) |
| "Inflammatory breast cancer (IBC) accounts for 1% to 5% of all breast cancer cases." | 1.36 | Novel targeted therapies in inflammatory breast cancer. ( Cristofanilli, M, 2010) |
| "Mucositis was induced on day 5 by 5-FU injection (150mg/kg i." | 1.35 | Lyprinol only partially improves indicators of small intestinal integrity in a rat model of 5-fluorouracil-induced mucositis. ( Butler, RN; Geier, MS; Howarth, GS; Smith, CL; Tooley, KL; Torres, DM, 2008) |
| "She was diagnosed as inflammatory breast cancer clinically and invasive ductal carcinoma with lymphatic invasion pathologically." | 1.34 | [A case of inflammatory breast cancer achieving pathological complete response by primary systemic therapy with CEF (cyclophosphamide, epirubicin, 5-fluorouracil) followed by docetaxel]. ( Ando, M; Matsuyama, Y; Ooi, Y; Rai, Y; Sagara, Y; Takahama, T; Tamada, S; Tsuchimochi, S, 2007) |
| "Male breast cancer is very rare, especially inflammatory breast cancer, which is an aggressive, rapidly proliferating manifestation of primary breast carcinoma." | 1.33 | Inflammatory breast cancer in a male. ( Choueiri, MB; El Saghir, NS; El-Hajj, II; Otrock, ZK; Tawil, AN, 2005) |
| "Sixty-eight patients with inflammatory breast carcinoma (IBC) received treatment in 2 prospective randomized trials of multimodality therapy for locally advanced breast cancer." | 1.32 | Long-term results of combined-modality therapy for inflammatory breast carcinoma. ( Baldini, E; Collecchi, P; Evagelista, G; Gardin, G; Lionetto, R; Prochilo, T, 2004) |
| "Chemotherapy is 1 method for the treatment of cancer, but serious side effects can sometimes limit the dosage given." | 1.32 | Simultaneous onset of acute inflammatory response, sepsis-like symptoms and intestinal mucosal injury after cancer chemotherapy. ( Fukushima, R; Hiki, N; Kaminishi, M; Kojima, J; Mafune, K; Mimura, Y; Nomura, S; Ogawa, T; Tsuji, E, 2003) |
| "All of the gallbladders had significant arteritis, with narrowing or occlusion of lumina or necrosis of vessel walls." | 1.27 | Chemical cholecystitis associated with hepatic arterial chemotherapy delivered by a permanently implanted pump. ( Dakhil, SR; Housholder, DF; Marymont, JV; Travers, H, 1985) |
| "Pre-treatment with colchicine or 5-fluorouracil to reduce cell accumulation was not found to effect the modified PGE2 response." | 1.27 | Studies of eicosanoid production in the air pouch model of synovial inflammation. ( Lees, P; Sedgwick, AD, 1986) |
| "Twenty-two patients with inflammatory breast carcinoma received preoperative chemotherapy consisting of weekly administration of cyclophosphamide, doxorubicin hydrochloride, fluorouracil, and vincristine sulfate for six weeks." | 1.27 | Inflammatory breast carcinoma. Effective multimodal approach. ( Burton, GV; Cox, EB; Hart, LL; Iglehart, JD; Leight, GS; Olsen, GA; Prosnitz, LR; Seigler, HF, 1987) |
| " 5-FU infusions with allopurinol as used in this regimen appear to offer no therapeutic advantage over a conventional dosing schedule." | 1.27 | Phase II trial of high-dose continuous infusion 5-fluorouracil with allopurinol modulation in colon cancer. ( Ahmann, FR; Garewal, H; Greenberg, BR, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 23 (16.79) | 18.7374 |
| 1990's | 8 (5.84) | 18.2507 |
| 2000's | 25 (18.25) | 29.6817 |
| 2010's | 52 (37.96) | 24.3611 |
| 2020's | 29 (21.17) | 2.80 |
| Authors | Studies |
|---|---|
| Saunders, MJ | 1 |
| Edwards, BS | 1 |
| Zhu, J | 1 |
| Sklar, LA | 1 |
| Graves, SW | 1 |
| Ma, S | 1 |
| Zhu, L | 1 |
| Fan, X | 1 |
| Luo, T | 1 |
| Liu, D | 1 |
| Liang, Z | 1 |
| Hu, X | 1 |
| Shi, T | 1 |
| Tan, W | 1 |
| Wang, Z | 1 |
| Mohamed, MZ | 1 |
| Mohammed, HH | 1 |
| Oliveira, MMB | 1 |
| de Araújo, AA | 1 |
| Ribeiro, SB | 1 |
| de Sales Mota, PCM | 1 |
| Marques, VB | 1 |
| da Silva Martins Rebouças, C | 1 |
| Figueiredo, JG | 1 |
| Barra, PB | 1 |
| de Castro Brito, GA | 2 |
| de Carvalho Leitão, RF | 1 |
| Guerra, GCB | 1 |
| de Medeiros, CACX | 1 |
| Kamposioras, K | 1 |
| Papaxoinis, G | 1 |
| Dawood, M | 1 |
| Appleyard, J | 1 |
| Collinson, F | 1 |
| Lamarca, A | 1 |
| Ahmad, U | 1 |
| Hubner, RA | 1 |
| Wright, F | 1 |
| Pihlak, R | 1 |
| Damyanova, I | 1 |
| Razzaq, B | 1 |
| Valle, JW | 1 |
| McNamara, MG | 1 |
| Anthoney, A | 1 |
| Chen, KJ | 1 |
| Huang, YL | 1 |
| Kuo, LM | 1 |
| Chen, YT | 1 |
| Hung, CF | 1 |
| Hsieh, PW | 1 |
| Yue, X | 1 |
| Wen, S | 1 |
| Long-Kun, D | 1 |
| Man, Y | 1 |
| Chang, S | 1 |
| Min, Z | 1 |
| Shuang-Yu, L | 1 |
| Xin, Q | 1 |
| Jie, M | 1 |
| Liang, W | 1 |
| Watts, K | 1 |
| Wills, C | 1 |
| Madi, A | 1 |
| Palles, C | 1 |
| Maughan, TS | 1 |
| Kaplan, R | 1 |
| Al-Tassan, NA | 1 |
| Kerr, R | 1 |
| Kerr, DJ | 1 |
| Houlston, RS | 1 |
| Escott-Price, V | 1 |
| Cheadle, JP | 1 |
| Wu, CF | 2 |
| Wu, CY | 2 |
| Lin, CF | 2 |
| Liu, YW | 1 |
| Lin, TC | 2 |
| Liao, HJ | 1 |
| Chang, GR | 2 |
| Tian, MM | 1 |
| Wang, YS | 1 |
| Xiao, HB | 1 |
| de Andrade, GL | 1 |
| da Silva Souza, B | 1 |
| Araújo, DD | 1 |
| de Freitas, CDT | 1 |
| de Oliveira, JS | 1 |
| Šuler Baglama, Š | 1 |
| Peteln, I | 1 |
| Jemec, GBE | 1 |
| Xia, J | 1 |
| Chen, J | 1 |
| Vashisth, MK | 1 |
| Ge, Y | 1 |
| Dai, Q | 1 |
| He, S | 1 |
| Shi, YL | 1 |
| Wang, XB | 1 |
| Zhang, Y | 1 |
| Xi, Y | 1 |
| Yang, C | 1 |
| Gong, W | 1 |
| Wang, C | 2 |
| Wu, L | 1 |
| Wang, D | 1 |
| Wzorek França Dos Santos, I | 1 |
| Sauruk da Silva, K | 1 |
| Regis Bueno, L | 1 |
| Suzane Schneider, V | 1 |
| Silva Schiebel, C | 1 |
| Mulinari Turin de Oliveira, N | 1 |
| Cristine Malaquias da Silva, L | 1 |
| Soares Fernandes, E | 1 |
| Biondaro Gois, M | 1 |
| Mach Cortes Cordeiro, L | 1 |
| Maria-Ferreira, D | 1 |
| van 't Land, FR | 1 |
| Aziz, MH | 1 |
| Michiels, N | 1 |
| Mieog, JSD | 1 |
| Bonsing, BA | 1 |
| Luelmo, SAC | 1 |
| Homs, MYV | 1 |
| Groot Koerkamp, B | 1 |
| Papageorgiou, G | 1 |
| van Eijck, CHJ | 1 |
| Alotayk, LI | 1 |
| Aldubayan, MA | 1 |
| Alenezi, SK | 1 |
| Anwar, MJ | 1 |
| Alhowail, AH | 1 |
| Hu, Q | 1 |
| Xu, J | 1 |
| Ke, J | 1 |
| Zhang, Z | 1 |
| Chu, T | 1 |
| Justino, PFC | 1 |
| Franco, AX | 2 |
| Pontier-Bres, R | 1 |
| Monteiro, CES | 1 |
| Barbosa, ALR | 1 |
| Souza, MHLP | 1 |
| Czerucka, D | 1 |
| Soares, PMG | 1 |
| Cha, YJ | 1 |
| Park, EJ | 1 |
| Baik, SH | 1 |
| Lee, KY | 1 |
| Kang, J | 1 |
| Zheng, JH | 1 |
| Lin, SR | 1 |
| Tseng, FJ | 1 |
| Tsai, MJ | 1 |
| Lue, SI | 1 |
| Chia, YC | 1 |
| Woon, M | 1 |
| Fu, YS | 1 |
| Weng, CF | 1 |
| Gan, Y | 2 |
| Ai, G | 1 |
| Wu, J | 2 |
| Luo, H | 2 |
| Chen, L | 2 |
| Huang, Q | 1 |
| Wu, X | 2 |
| Xu, N | 2 |
| Li, M | 3 |
| Su, Z | 2 |
| Liu, Y | 2 |
| Huang, X | 1 |
| Liang, J | 1 |
| Zhuo, J | 1 |
| Wu, Q | 1 |
| Lin, Z | 1 |
| Clarke, SJ | 2 |
| Burge, M | 2 |
| Feeney, K | 1 |
| Gibbs, P | 3 |
| Jones, K | 1 |
| Marx, G | 1 |
| Molloy, MP | 1 |
| Price, T | 1 |
| Reece, WHH | 1 |
| Segelov, E | 1 |
| Tebbutt, NC | 1 |
| Mendoza-Rodríguez, MG | 1 |
| Sánchez-Barrera, CÁ | 1 |
| Callejas, BE | 1 |
| García-Castillo, V | 1 |
| Beristain-Terrazas, DL | 1 |
| Delgado-Buenrostro, NL | 1 |
| Chirino, YI | 1 |
| León-Cabrera, SA | 1 |
| Rodríguez-Sosa, M | 1 |
| Gutierrez-Cirlos, EB | 1 |
| Pérez-Plasencia, C | 1 |
| Vaca-Paniagua, F | 1 |
| Meraz-Ríos, MA | 1 |
| Terrazas, LI | 1 |
| Ahmad, SI | 1 |
| Fideles, LS | 1 |
| de Miranda, JAL | 1 |
| Martins, CDS | 1 |
| Barbosa, MLL | 1 |
| Pimenta, HB | 1 |
| Pimentel, PVS | 1 |
| Teixeira, CS | 1 |
| Scafuri, MAS | 1 |
| Façanha, SO | 1 |
| Barreto, JEF | 1 |
| Carvalho, PMM | 1 |
| Scafuri, AG | 1 |
| Araújo, JL | 1 |
| Rocha, JA | 1 |
| Vieira, IGP | 1 |
| Ricardo, NMPS | 1 |
| da Silva Campelo, M | 1 |
| Ribeiro, MENP | 1 |
| Cerqueira, GS | 1 |
| McQuade, RM | 1 |
| Al Thaalibi, M | 1 |
| Nurgali, K | 1 |
| Elghareeb, MM | 1 |
| Elshopakey, GE | 1 |
| Hendam, BM | 1 |
| Rezk, S | 1 |
| Lashen, S | 1 |
| Gupta, N | 1 |
| Ferreira, J | 1 |
| Hong, CHL | 1 |
| Tan, KS | 1 |
| Tefas, C | 1 |
| Ciobanu, L | 1 |
| Berce, C | 1 |
| Meșter, A | 1 |
| Onica, S | 1 |
| Toma, C | 1 |
| Tanțău, M | 1 |
| Taulescu, M | 1 |
| Chiou, RY | 1 |
| Yang, WC | 1 |
| Wang, CM | 1 |
| Hou, PH | 1 |
| Kuo, CY | 1 |
| Huo, X | 1 |
| Gao, L | 1 |
| Sun, G | 1 |
| Li, C | 1 |
| Kato, S | 2 |
| Hamouda, N | 1 |
| Kano, Y | 1 |
| Oikawa, Y | 1 |
| Tanaka, Y | 1 |
| Matsumoto, K | 1 |
| Amagase, K | 1 |
| Shimakawa, M | 1 |
| Forsgård, RA | 1 |
| Marrachelli, VG | 1 |
| Korpela, K | 1 |
| Frias, R | 1 |
| Collado, MC | 1 |
| Korpela, R | 1 |
| Monleon, D | 1 |
| Spillmann, T | 1 |
| Österlund, P | 2 |
| Li, HL | 1 |
| Lu, L | 1 |
| Wang, XS | 1 |
| Qin, LY | 1 |
| Wang, P | 1 |
| Qiu, SP | 1 |
| Wu, H | 1 |
| Huang, F | 1 |
| Zhang, BB | 1 |
| Shi, HL | 1 |
| Wu, XJ | 1 |
| Mina, M | 1 |
| Elgarhy, L | 1 |
| Al-Saeid, H | 1 |
| Ibrahim, Z | 1 |
| Liu, XY | 1 |
| Zhang, FR | 1 |
| Shang, JY | 1 |
| Liu, YY | 1 |
| Lv, XF | 1 |
| Yuan, JN | 1 |
| Zhang, TT | 1 |
| Li, K | 1 |
| Lin, XC | 1 |
| Liu, X | 1 |
| Lei, Q | 1 |
| Fu, XD | 1 |
| Zhou, JG | 1 |
| Liang, SJ | 1 |
| de Barros, PAV | 1 |
| Rabelo Andrade, ME | 1 |
| de Vasconcelos Generoso, S | 1 |
| Mendes Miranda, SE | 1 |
| Dos Reis, DC | 1 |
| Lacerda Leocádio, PC | 1 |
| de Sales E Souza, ÉL | 1 |
| Dos Santos Martins, F | 1 |
| da Gama, MAS | 1 |
| Cassali, GD | 1 |
| Alvarez Leite, JI | 1 |
| Antunes Fernandes, SO | 1 |
| Cardoso, VN | 1 |
| Levit, R | 1 |
| Savoy de Giori, G | 1 |
| de Moreno de LeBlanc, A | 1 |
| LeBlanc, JG | 1 |
| Park, JW | 1 |
| Oh, J | 1 |
| Ko, SJ | 1 |
| Chang, MS | 1 |
| Kim, J | 1 |
| Carvalho, R | 1 |
| Vaz, A | 1 |
| Pereira, FL | 1 |
| Dorella, F | 1 |
| Aguiar, E | 1 |
| Chatel, JM | 1 |
| Bermudez, L | 1 |
| Langella, P | 1 |
| Fernandes, G | 1 |
| Figueiredo, H | 1 |
| Goes-Neto, A | 1 |
| Azevedo, V | 1 |
| Yang, X | 1 |
| Daifallah, AEM | 1 |
| Shankar, S | 1 |
| Beer, J | 1 |
| Marshall, C | 1 |
| Dentchev, T | 1 |
| Seykora, F | 1 |
| D'Armas, S | 1 |
| Hahn, J | 1 |
| Lee, V | 1 |
| Sabry, HH | 1 |
| Farag, AM | 1 |
| Seykora, JT | 1 |
| Voiculescu, VM | 1 |
| Lisievici, CV | 1 |
| Lupu, M | 1 |
| Vajaitu, C | 1 |
| Draghici, CC | 1 |
| Popa, AV | 1 |
| Solomon, I | 1 |
| Sebe, TI | 1 |
| Constantin, MM | 1 |
| Caruntu, C | 1 |
| Sougiannis, AT | 1 |
| VanderVeen, BN | 1 |
| Enos, RT | 1 |
| Velazquez, KT | 1 |
| Bader, JE | 1 |
| Carson, M | 1 |
| Chatzistamou, I | 1 |
| Walla, M | 1 |
| Pena, MM | 3 |
| Kubinak, JL | 1 |
| Nagarkatti, M | 1 |
| Carson, JA | 1 |
| Murphy, EA | 3 |
| Barbosa, SCM | 1 |
| Pereira, VBM | 1 |
| Wong, DVT | 1 |
| Santana, APM | 1 |
| Lucetti, LT | 1 |
| Carvalho, LL | 1 |
| Barbosa, CRN | 1 |
| Callado, RB | 1 |
| Silva, CAA | 1 |
| Lopes, CDH | 1 |
| Brito, GAC | 1 |
| Alencar, NMN | 1 |
| Lima-Júnior, RCP | 1 |
| Hong, BY | 1 |
| Sobue, T | 1 |
| Choquette, L | 1 |
| Dupuy, AK | 1 |
| Thompson, A | 1 |
| Burleson, JA | 1 |
| Salner, AL | 1 |
| Schauer, PK | 1 |
| Joshi, P | 1 |
| Fox, E | 1 |
| Shin, DG | 1 |
| Weinstock, GM | 1 |
| Strausbaugh, LD | 1 |
| Dongari-Bagtzoglou, A | 1 |
| Peterson, DE | 1 |
| Diaz, PI | 1 |
| Clarke, S | 1 |
| Cordwell, C | 1 |
| Reece, W | 1 |
| Tebbutt, N | 1 |
| Briones, TL | 1 |
| Woods, J | 2 |
| Robinson, SM | 1 |
| Mann, DA | 1 |
| Manas, DM | 1 |
| Oakley, F | 1 |
| Mann, J | 1 |
| White, SA | 1 |
| Alkhateeb, A | 1 |
| Zubritsky, L | 1 |
| Kinsman, B | 1 |
| Leitzel, K | 1 |
| Campbell-Baird, C | 1 |
| Ali, SM | 1 |
| Connor, J | 1 |
| Lipton, A | 1 |
| Wei, G | 1 |
| Nie, MM | 1 |
| Shen, XJ | 1 |
| Xue, XC | 1 |
| Ma, LY | 1 |
| Du, CH | 1 |
| Wang, SL | 1 |
| Bi, JW | 1 |
| Mahoney, SE | 2 |
| Davis, JM | 2 |
| McClellan, JL | 2 |
| Lee, CS | 1 |
| Ryan, EJ | 1 |
| Doherty, GA | 1 |
| Uyeturk, U | 1 |
| Gucuk, A | 1 |
| Firat, T | 1 |
| Kemahli, E | 1 |
| Kukner, A | 1 |
| Ozyalvacli, ME | 1 |
| Whittaker, AL | 1 |
| Lymn, KA | 1 |
| Nicholson, A | 1 |
| Howarth, GS | 4 |
| Formica, V | 1 |
| Luccchetti, J | 1 |
| Cunningham, D | 1 |
| Smyth, EC | 1 |
| Ferroni, P | 1 |
| Nardecchia, A | 1 |
| Tesauro, M | 1 |
| Cereda, V | 1 |
| Guadagni, F | 1 |
| Roselli, M | 1 |
| Bellamkonda, K | 1 |
| Sime, W | 1 |
| Sjölander, A | 1 |
| Vasudevan, A | 1 |
| Yu, Y | 1 |
| Banerjee, S | 1 |
| Farhana, L | 1 |
| Rajendra, SG | 1 |
| Patel, A | 1 |
| Dyson, G | 1 |
| Levi, E | 1 |
| Maddipati, KR | 1 |
| Majumdar, AP | 1 |
| Nangia-Makker, P | 1 |
| Dzhugashvili, M | 1 |
| Luengo-Gil, G | 1 |
| García, T | 1 |
| González-Conejero, R | 1 |
| Conesa-Zamora, P | 1 |
| Escolar, PP | 1 |
| Calvo, F | 1 |
| Vicente, V | 1 |
| Ayala de la Peña, F | 1 |
| Skeff, MA | 1 |
| Brito, GA | 1 |
| de Oliveira, MG | 1 |
| Braga, CM | 1 |
| Cavalcante, MM | 1 |
| Baldim, V | 1 |
| Holanda-Afonso, RC | 1 |
| Silva-Boghossian, CM | 1 |
| Colombo, AP | 1 |
| Ribeiro, RA | 2 |
| Moura-Neto, V | 1 |
| Leitão, RF | 1 |
| Justino, PF | 1 |
| Melo, LF | 1 |
| Nogueira, AF | 1 |
| Morais, CM | 1 |
| Mendes, WO | 1 |
| Souza, EP | 1 |
| Souza, MH | 1 |
| Soares, PM | 1 |
| Nakamura, K | 1 |
| Sasayama, A | 1 |
| Takahashi, T | 1 |
| Yamaji, T | 1 |
| Theodoro, LH | 1 |
| Longo, M | 1 |
| Ervolino, E | 1 |
| Duque, C | 1 |
| Ferro-Alves, ML | 1 |
| Assem, NZ | 1 |
| Louzada, LM | 1 |
| Garcia, VG | 1 |
| Trace, AP | 1 |
| Enos, CW | 1 |
| Mantel, A | 1 |
| Harvey, VM | 1 |
| Dygai, AM | 1 |
| Skurikhin, EG | 1 |
| Pershina, OV | 1 |
| Ermakova, NN | 1 |
| Krupin, VA | 1 |
| Ermolaeva, LA | 1 |
| Stakheeva, MN | 1 |
| Choinzonov, EL | 1 |
| Goldberg, VE | 1 |
| Reikhart, DV | 1 |
| Ellinidi, VN | 1 |
| Kravtsov, VY | 1 |
| Song, N | 1 |
| Pogue-Geile, KL | 1 |
| Gavin, PG | 1 |
| Yothers, G | 1 |
| Kim, SR | 1 |
| Johnson, NL | 1 |
| Lipchik, C | 1 |
| Allegra, CJ | 1 |
| Petrelli, NJ | 1 |
| O'Connell, MJ | 1 |
| Wolmark, N | 1 |
| Paik, S | 1 |
| Tang, Y | 1 |
| Wu, Y | 1 |
| Huang, Z | 1 |
| Dong, W | 1 |
| Deng, Y | 1 |
| Wang, F | 1 |
| Yuan, J | 1 |
| Al-Asmari, AK | 1 |
| Khan, AQ | 1 |
| Al-Asmari, SA | 1 |
| Al-Rawi, A | 1 |
| Al-Omani, S | 1 |
| Sommer, J | 1 |
| Mahli, A | 1 |
| Freese, K | 1 |
| Schiergens, TS | 1 |
| Kuecuekoktay, FS | 1 |
| Teufel, A | 1 |
| Thasler, WE | 1 |
| Müller, M | 1 |
| Bosserhoff, AK | 1 |
| Hellerbrand, C | 1 |
| Inoue, Y | 1 |
| Hazama, S | 1 |
| Suzuki, N | 1 |
| Tokumitsu, Y | 1 |
| Kanekiyo, S | 1 |
| Tomochika, S | 1 |
| Tsunedomi, R | 1 |
| Tokuhisa, Y | 1 |
| Iida, M | 1 |
| Sakamoto, K | 1 |
| Takeda, S | 1 |
| Ueno, T | 1 |
| Yoshino, S | 1 |
| Nagano, H | 1 |
| Logan, RM | 1 |
| Stringer, AM | 1 |
| Bowen, JM | 1 |
| Gibson, RJ | 1 |
| Sonis, ST | 1 |
| Keefe, DM | 1 |
| Park, CW | 1 |
| Rhee, YS | 1 |
| Park, SH | 1 |
| Danh, SD | 1 |
| Ahn, SH | 1 |
| Chi, SC | 1 |
| Park, ES | 1 |
| Cristofanilli, M | 1 |
| Woodward, WA | 1 |
| Debeb, BG | 1 |
| Xu, W | 1 |
| Buchholz, TA | 1 |
| Vemula, S | 1 |
| Ramdas, B | 1 |
| Hanneman, P | 1 |
| Martin, J | 1 |
| Beggs, HE | 1 |
| Kapur, R | 1 |
| Raghu Nadhanan, R | 1 |
| Abimosleh, SM | 1 |
| Su, YW | 1 |
| Scherer, MA | 1 |
| Xian, CJ | 2 |
| Karaaltin, MV | 1 |
| Ozalp, B | 1 |
| Dadaci, M | 1 |
| Kayikcioglu, A | 1 |
| Kecik, A | 1 |
| Oner, F | 1 |
| Moysidis, SN | 1 |
| Thanos, A | 1 |
| Vavvas, DG | 1 |
| Gordon, B | 1 |
| Masters, SL | 1 |
| Gerlic, M | 1 |
| Metcalf, D | 1 |
| Preston, S | 1 |
| Pellegrini, M | 1 |
| O'Donnell, JA | 1 |
| McArthur, K | 1 |
| Baldwin, TM | 1 |
| Chevrier, S | 1 |
| Nowell, CJ | 1 |
| Cengia, LH | 1 |
| Henley, KJ | 1 |
| Collinge, JE | 1 |
| Kastner, DL | 1 |
| Feigenbaum, L | 1 |
| Hilton, DJ | 1 |
| Alexander, WS | 1 |
| Kile, BT | 1 |
| Croker, BA | 1 |
| Orpana, A | 1 |
| Elomaa, I | 1 |
| Repo, H | 1 |
| Joensuu, H | 1 |
| Tsuji, E | 1 |
| Hiki, N | 1 |
| Nomura, S | 1 |
| Fukushima, R | 1 |
| Kojima, J | 1 |
| Ogawa, T | 1 |
| Mafune, K | 1 |
| Mimura, Y | 1 |
| Kaminishi, M | 1 |
| PAGE, AR | 2 |
| Choi, EA | 1 |
| Lei, H | 1 |
| Maron, DJ | 1 |
| Mick, R | 1 |
| Barsoum, J | 1 |
| Yu, QC | 1 |
| Fraker, DL | 1 |
| Wilson, JM | 1 |
| Spitz, FR | 1 |
| Efficace, F | 1 |
| Therasse, P | 1 |
| Piccart, MJ | 1 |
| Coens, C | 1 |
| van Steen, K | 1 |
| Welnicka-Jaskiewicz, M | 1 |
| Cufer, T | 1 |
| Dyczka, J | 1 |
| Lichinitser, M | 1 |
| Shepherd, L | 1 |
| de Haes, H | 1 |
| Sprangers, MA | 1 |
| Bottomley, A | 1 |
| Iguchi, H | 1 |
| Kusuki, M | 1 |
| Nakamura, A | 1 |
| Nishiura, H | 1 |
| Kanazawa, A | 1 |
| Takayama, M | 1 |
| Sunami, K | 1 |
| Yamane, H | 1 |
| Baldini, E | 1 |
| Gardin, G | 1 |
| Evagelista, G | 1 |
| Prochilo, T | 1 |
| Collecchi, P | 1 |
| Lionetto, R | 1 |
| Cool, JC | 1 |
| Dyer, JL | 1 |
| Butler, RN | 2 |
| Geier, MS | 2 |
| Choueiri, MB | 1 |
| Otrock, ZK | 1 |
| Tawil, AN | 1 |
| El-Hajj, II | 1 |
| El Saghir, NS | 1 |
| Cincik, H | 1 |
| Güngör, A | 1 |
| Sağlam, O | 1 |
| Cekin, E | 1 |
| Yildirim, S | 1 |
| Poyrazoğlu, E | 1 |
| Lim, L | 1 |
| Yip, D | 1 |
| Shapiro, JD | 1 |
| Dowling, R | 1 |
| Smith, D | 1 |
| Little, A | 1 |
| Bailey, W | 1 |
| Liechtenstein, M | 1 |
| Jansen, C | 1 |
| Miaskowski, C | 1 |
| Dodd, M | 1 |
| Dowling, G | 1 |
| Kramer, J | 1 |
| Nieto, Y | 1 |
| Santisteban, M | 1 |
| Aramendía, JM | 1 |
| Fernández-Hidalgo, O | 1 |
| García-Manero, M | 1 |
| López, G | 1 |
| Crozier, JE | 1 |
| McKee, RF | 1 |
| McArdle, CS | 1 |
| Angerson, WJ | 1 |
| Anderson, JH | 1 |
| Horgan, PG | 1 |
| McMillan, DC | 1 |
| Gupta, SK | 1 |
| Gupta, M | 1 |
| Hoffman, B | 1 |
| Liebermann, DA | 1 |
| Read, JA | 1 |
| Beale, PJ | 1 |
| Volker, DH | 1 |
| Smith, N | 1 |
| Childs, A | 1 |
| Veyret, C | 1 |
| Levy, C | 1 |
| Chollet, P | 1 |
| Merrouche, Y | 1 |
| Roche, H | 1 |
| Kerbrat, P | 1 |
| Fumoleau, P | 1 |
| Fargeot, P | 1 |
| Clavere, P | 1 |
| Chevallier, B | 1 |
| Sagara, Y | 3 |
| Rai, Y | 1 |
| Tamada, S | 1 |
| Tsuchimochi, S | 1 |
| Takahama, T | 1 |
| Matsuyama, Y | 1 |
| Ando, M | 1 |
| Ooi, Y | 1 |
| Milivojević, M | 1 |
| Vukosavljević, M | 1 |
| Aleksić, P | 1 |
| Stojković, R | 1 |
| Dimitrijević, J | 1 |
| Latković, Z | 1 |
| Avramović, S | 1 |
| Torres, DM | 1 |
| Tooley, KL | 1 |
| Smith, CL | 1 |
| Sugae, S | 1 |
| Suzuki, A | 1 |
| Takahashi, N | 1 |
| Minamimoto, R | 1 |
| Cheng, C | 1 |
| Theeraladanon, C | 1 |
| Endo, I | 1 |
| Togo, S | 1 |
| Inoue, T | 1 |
| Shimada, H | 1 |
| Krathen, M | 1 |
| Treat, J | 1 |
| James, WD | 1 |
| Connolly, KM | 1 |
| Diasio, RB | 1 |
| Armstrong, RD | 1 |
| Kaplan, AM | 1 |
| Howell, SB | 1 |
| Pfeifle, CE | 1 |
| Wung, WE | 1 |
| Valet, G | 1 |
| Warnecke, HH | 1 |
| Kahle, H | 1 |
| Costa, MJ | 1 |
| Stewart, G | 1 |
| Perez, EA | 1 |
| Goodnight, JE | 1 |
| Rodier, JM | 1 |
| Malbec, L | 1 |
| Lauraine, EP | 1 |
| Batel-Copel, L | 1 |
| Bernadou, A | 1 |
| Fitzpatrick, RE | 1 |
| Mackay, HJ | 1 |
| Williamson, EC | 1 |
| Vasey, P | 1 |
| Harnett, AN | 1 |
| Yamano, T | 1 |
| Takayasu, Y | 1 |
| Nakao, N | 1 |
| Kubota, A | 1 |
| El-Malt, M | 1 |
| Ceelen, W | 1 |
| van den Broecke, C | 1 |
| Cuvelier, C | 1 |
| Van Belle, S | 1 |
| De Neve, W | 1 |
| de Hemptinne, B | 1 |
| Pattyn, P | 1 |
| Mantovani, G | 1 |
| Proto, E | 1 |
| Massa, E | 1 |
| Mulas, C | 1 |
| Madeddu, C | 1 |
| Mura, L | 1 |
| Mudu, MC | 1 |
| Astara, G | 1 |
| Murgia, V | 1 |
| Gramignano, G | 1 |
| Ferreli, L | 1 |
| Camboni, P | 1 |
| Lusso, MR | 1 |
| Mocci, M | 1 |
| Tore, G | 1 |
| Mura, M | 1 |
| Amichetti, M | 1 |
| Maccio, A | 1 |
| Tanaka, T | 1 |
| Miyamoto, K | 1 |
| Tsubosaki, M | 1 |
| Yamashita, T | 1 |
| Isawa, S | 1 |
| Firstater, M | 1 |
| Meshorer, A | 1 |
| Tadmor, A | 1 |
| Itzicovitch, L | 1 |
| Pisansky, TM | 1 |
| Schaid, DJ | 1 |
| Loprinzi, CL | 1 |
| Donohue, JH | 1 |
| Schray, MF | 1 |
| Schomberg, PJ | 1 |
| Hook, CC | 1 |
| Kimmel, DW | 1 |
| Kvols, LK | 1 |
| Scheithauer, BW | 1 |
| Forsyth, PA | 1 |
| Rubin, J | 1 |
| Moertel, CG | 1 |
| Rodriguez, M | 1 |
| Campana, F | 1 |
| Palangié, T | 1 |
| Fourquet, A | 1 |
| Pouillart, P | 1 |
| Vilcoq, JR | 1 |
| Jampel, HD | 1 |
| Jabs, DA | 1 |
| Quigley, HA | 1 |
| Weinreb, RN | 1 |
| Figoli, F | 1 |
| Chiarion Sileni, V | 1 |
| Gulisano, M | 1 |
| Maggian, P | 1 |
| Fosser, V | 1 |
| Marymont, JV | 1 |
| Dakhil, SR | 1 |
| Travers, H | 1 |
| Housholder, DF | 1 |
| Pluzanska, A | 1 |
| Stempczynska, J | 1 |
| Wolska, H | 1 |
| Szmigielski, S | 1 |
| Jeljaszewicz, J | 1 |
| Pulverer, G | 1 |
| Sedgwick, AD | 1 |
| Lees, P | 1 |
| Burton, GV | 1 |
| Cox, EB | 1 |
| Leight, GS | 1 |
| Prosnitz, LR | 1 |
| Iglehart, JD | 1 |
| Olsen, GA | 1 |
| Seigler, HF | 1 |
| Hart, LL | 1 |
| Rouëssé, J | 1 |
| Friedman, S | 1 |
| Sarrazin, D | 1 |
| Mouriesse, H | 1 |
| Le Chevalier, T | 1 |
| Arriagada, R | 1 |
| Spielmann, M | 1 |
| Papacharalambous, A | 1 |
| May-Levin, F | 1 |
| Kasimis, BS | 1 |
| Miller, JB | 1 |
| Kaneshiro, CA | 1 |
| Forbes, KA | 1 |
| Moran, EM | 1 |
| Metter, GE | 1 |
| Ahmann, FR | 1 |
| Garewal, H | 1 |
| Greenberg, BR | 1 |
| Tsvetkova, GM | 1 |
| Leshchenko, VM | 1 |
| Vail, JT | 1 |
| Litwin, MS | 2 |
| Ryan, RF | 2 |
| Ichinose, H | 1 |
| Reed, RR | 1 |
| Kremetz, ET | 1 |
| Mörsdorf, K | 1 |
| Knippertz, T | 1 |
| Rausch, KD | 1 |
| Domenjoz, R | 1 |
| Reed, RJ | 1 |
| Krementz, ET | 1 |
| Torre, D | 2 |
| Omura, EF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Australian Translational Study to Evaluate the Prognostic Role of Inflammatory Markers in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab (Avastin™)[NCT01588990] | Phase 4 | 128 participants (Actual) | Interventional | 2012-06-26 | Completed | ||
| The Effectiveness of Topical Oral Vitamin D Gel in Prevention of Radiation-induced Oral Mucositis[NCT04308161] | Phase 2 | 45 participants (Anticipated) | Interventional | 2019-11-02 | Recruiting | ||
| The Effectiveness of Melatonin in Prevention of Radiation-induced Oral Mucositis[NCT03833570] | Phase 2 | 40 participants (Actual) | Interventional | 2018-01-12 | Completed | ||
| A Clinical Trial Comparing 5-Fluorouracil (5-FU) Plus Leucovorin (LV) and Oxaliplatin With 5-FU Plus LV for the Treatment of Patients With Stages II and III Carcinoma of the Colon[NCT00004931] | Phase 3 | 2,472 participants (Anticipated) | Interventional | 2000-02-29 | Completed | ||
| The Effect of Alpha Lipoic Acid on the Incidence and Severity of Radiotherapy-Induced Oral Mucositis in Head and Neck Cancer Patients[NCT05023863] | Phase 2/Phase 3 | 70 participants (Anticipated) | Interventional | 2021-09-01 | Not yet recruiting | ||
| Phase 3 Study of Enteral Nutrition Rich in Eicosapentaenoic Acid in Patients Receiving Chemotherapy for Gastric Cancer or Colorectal Cancer[NCT01048463] | Phase 3 | 90 participants (Anticipated) | Interventional | 2009-12-31 | Recruiting | ||
| A Prospective Multicenter Open-label, Randomized Phase II Study of Pembrolizumab in Combination With Neoadjuvant EC-Paclitaxel Regimen in HER2-negative Inflammatory Breast Cancer.[NCT03515798] | Phase 2 | 81 participants (Anticipated) | Interventional | 2018-07-24 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
NLR was calculated from the laboratory values as the ratio of Neutrophils to Lymphocytes. Longitudinal NLR was assessed by treating the NLR measurements taken over the time-course of treatment as a time-dependent covariate. OS was defined as the time from the start of initial treatment to the date of death, regardless of the cause of death. The association between longitudinal NLR (longitudinal NLR ≤5 vs NLR >5) and OS was reported as hazard ratio. (NCT01588990)
Timeframe: Baseline up to death or end of study (up to 4 years)
| Intervention | hazard ratio (Number) |
|---|---|
| Bevacizumab: Phase A and Phase B | 2.2 |
NLR was calculated from the laboratory values as the ratio of Neutrophils to Lymphocytes. Longitudinal NLR was assessed by treating the NLR measurements taken over the time-course of treatment as a time-dependent covariate. PFS was defined as time from the start of initial treatment to documentation of first disease progression or death from any cause, whichever occurred first. Disease progression was determined according to standard practice based on radiological, biochemical (CEA) or clinical factors. Determination of disease progression was to be unequivocal and was defined as: an unequivocal and clinically meaningful increase in size of known tumors, appearance of one or more new lesions, death due to disease without prior objective documentation of progression, elevated CEA accompanied by other radiological or clinical evidence of progression, or symptomatic deterioration. The association between longitudinal NLR (longitudinal NLR ≤5 vs N>5) and PFS was reported as hazard ratio. (NCT01588990)
Timeframe: Baseline up to disease progression, death or end of study (up to 4 years)
| Intervention | hazard ratio (Number) |
|---|---|
| Bevacizumab: Phase A and Phase B | 1.3 |
NLR was calculated from the laboratory values as the ratio of Neutrophils to Lymphocytes. PFS was defined as the time from the start of initial treatment to documentation of first disease progression or death from any cause, whichever occurred first. Disease progression was determined according to standard practice based on radiological, biochemical (carcinoembryonic antigen [CEA]) or clinical factors. Determination of disease progression was to be unequivocal and was defined as any of the following: an unequivocal and clinically meaningful increase in the size of known tumors, the appearance of one or more new lesions, death due to disease without prior objective documentation of progression, elevated CEA accompanied by other radiological or clinical evidence of progression, or symptomatic deterioration. The association between NLR (NLR less than or equal to [≤] 5 vs greater than [>] 5) and PFS was reported as hazard ratio. (NCT01588990)
Timeframe: Baseline up to disease progression, death or end of study (up to 4 years)
| Intervention | hazard ratio (Number) |
|---|---|
| Bevacizumab: Phase A and Phase B | 1.4 |
NLR was calculated from the laboratory values as the ratio of Neutrophils to Lymphocytes. OS was defined as the time from the start of initial treatment to the date of death, regardless of the cause of death. The association between NLR (NLR ≤ 5 vs > 5) and OS was reported as hazard ratio. (NCT01588990)
Timeframe: Baseline up to disease progression, death or end of study (up to 4 years)
| Intervention | hazard ratio (Number) |
|---|---|
| Bevacizumab: Phase A and Phase B | 1.6 |
NLR was calculated from laboratory values as ratio of Neutrophils to Lymphocytes. NLR normalization was assessed by adding first post-baseline measurement of NLR to the primary model. This is equivalent to testing whether first change in NLR is significantly associated with outcome. PFS was defined as time from start of initial treatment to documentation of first disease progression or death from any cause. Disease progression was determined according to standard practice based on radiological, biochemical (CEA) or clinical factors. Determination of disease progression was defined as: an unequivocal and clinically meaningful increase in size of known tumors, appearance of ≥1 new lesions, death due to disease without prior objective documentation of progression, elevated CEA accompanied by other radiological or clinical evidence of progression, or symptomatic deterioration.The association between NLR normalization (first NLR post-baseline ≤5 vs >5) and PFS was reported as hazard ratio. (NCT01588990)
Timeframe: Baseline up to disease progression, death or end of study (up to 4 years)
| Intervention | hazard ratio (Number) |
|---|---|
| Bevacizumab: Phase A and Phase B | 0.9 |
DDC was defined as PFS + PFS-B. In cases where a participant did not enter Phase B, then DDC was defined as PFS. PFS was defined as time from start of initial treatment to documentation of first disease progression or death from any cause, whichever occurred first. PFS-B was time from start of Phase B treatment to documentation of second disease progression or death from any cause, whichever occurred first. Disease progression was determined according to standard practice based on radiological, biochemical (CEA) or clinical factors. Determination of disease progression was to be unequivocal and was defined as any of the following: an unequivocal and clinically meaningful increase in the size of known tumors, appearance of one or more new lesions, death due to disease without prior objective documentation of progression, elevated CEA accompanied by other radiological or clinical evidence of progression, or symptomatic deterioration. Kaplan-Meier methodology was used to estimate DDC. (NCT01588990)
Timeframe: Baseline up to disease progression, death or end of study (up to 4 years)
| Intervention | months (Median) |
|---|---|
| Bevacizumab: Phase A and Phase B | 14.0 |
Overall Survival in Phase B was defined as the time from the start of treatment in Phase B to death due to any cause. Kaplan-Meier methodology was used to estimate OS. (NCT01588990)
Timeframe: From the start of Phase B treatment death or end of study (up to 4 years)
| Intervention | months (Median) |
|---|---|
| Bevacizumab: Phase B | 14.9 |
OS was defined as the time from the start of initial treatment to the date of death, regardless of the cause of death. Kaplan-Meier methodology was used to estimate OS. (NCT01588990)
Timeframe: Baseline until death or end of study (up to 4 years)
| Intervention | months (Median) |
|---|---|
| Bevacizumab: Phase A and Phase B | 25.0 |
The results include percentage of participants who underwent potentially curative liver resection. (NCT01588990)
Timeframe: Baseline up to disease progression, death or end of study (up to 4 years)
| Intervention | percentage of participants (Number) |
|---|---|
| Bevacizumab: Phase A and Phase B | 1.6 |
PFS until first progression was defined as the time from the start of initial treatment to documentation of first disease progression or death from any cause, whichever occurred first. Disease progression was determined according to standard practice based on radiological, biochemical (CEA) or clinical factors. Determination of disease progression was to be unequivocal and was defined as any of the following: an unequivocal and clinically meaningful increase in the size of known tumors, the appearance of one or more new lesions, death due to disease without prior objective documentation of progression, elevated CEA accompanied by other radiological or clinical evidence of progression, or symptomatic deterioration. Kaplan-Meier methodology was used to estimate PFS. (NCT01588990)
Timeframe: Baseline up to first disease progression, death or end of study (up to 4 years)
| Intervention | months (Median) |
|---|---|
| Bevacizumab: Phase A | 9.2 |
PFS in Phase B (PFS-B) was defined as the time from the start of Phase B treatment to documentation of second disease progression or death from any cause, whichever occurred first. Disease progression was determined according to standard practice based on radiological, biochemical (CEA) or clinical factors. Determination of disease progression was to be unequivocal and was defined as any of the following: an unequivocal and clinically meaningful increase in the size of known tumors, the appearance of one or more new lesions, death due to disease without prior objective documentation of progression, elevated CEA accompanied by other radiological or clinical evidence of progression, or symptomatic deterioration. Kaplan-Meier methodology was used to estimate PFS. (NCT01588990)
Timeframe: From the start of Phase B treatment to disease progression, death or end of study (up to 4 years)
| Intervention | months (Median) |
|---|---|
| Bevacizumab: Phase B | 6.7 |
Survival beyond first progression was defined as the time from the date of first disease progression to death due to any cause. Disease progression was determined according to standard practice based on radiological, biochemical (CEA) or clinical factors. Determination of disease progression was to be unequivocal and was defined as any of the following: an unequivocal and clinically meaningful increase in the size of known tumors, the appearance of one or more new lesions, death due to disease without prior objective documentation of progression, elevated CEA accompanied by other radiological or clinical evidence of progression, or symptomatic deterioration. Kaplan-Meier methodology was used to estimate survival beyond first disease progression. (NCT01588990)
Timeframe: Baseline until death or end of study (up to 4 years)
| Intervention | months (Median) |
|---|---|
| Bevacizumab: Phase A and Phase B | 12.6 |
TFS was defined as time from the start of initial treatment to documentation of first disease progression without entering Phase B, or second disease progression having entered Phase B. Disease progression was determined according to standard practice based on radiological, biochemical (CEA) or clinical factors. Determination of disease progression was to be unequivocal and was defined as any of the following: an unequivocal and clinically meaningful increase in the size of known tumors, the appearance of one or more new lesions, death due to disease without prior objective documentation of progression, elevated CEA accompanied by other radiological or clinical evidence of progression, or symptomatic deterioration. Kaplan-Meier methodology was used to estimate TFS. (NCT01588990)
Timeframe: Baseline up to disease progression, death or end of study (up to 4 years)
| Intervention | months (Median) |
|---|---|
| Bevacizumab: Phase A and Phase B | 14.8 |
AQoL-8D provides a global utility score and consists of 8 separately scored dimensions including Independent Living, Life Satisfaction, Mental Health, Coping, Relationships, Self Worth, Pain, and Senses. Each of the 8 scales is calculated based on the answers to 3 questions. Each question is given an answer dependent utility score (0 [worst] to 1 [best]) and then these scores are combined using a multiplicative model to get the normalized scale score value, each scale ranging between 0.0 (representing death) and 1.0 (representing full health). (NCT01588990)
Timeframe: Baseline, every 8-9 weeks thereafter, EOT (30 days after disease progression [up to 4 years]), survival follow-up 12-weekly visits (up to 4 years) [Detailed time points are presented in the category titles]
| Intervention | units on a scale (Mean) | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phase B Baseline | Phase B Visit 2 (up to 4 years) | Phase B Visit 3 (up to 4 years) | Phase B Visit 4 (up to 4 years) | Phase B Visit 5 (up to 4 years) | Phase B Visit 6 (up to 4 years) | Phase B Visit 7 (up to 4 years) | Phase B Visit 8 (up to 4 years) | Phase B Visit 9 (up to 4 years) | Phase B Visit 10 (up to 4 years) | Phase B Visit 11 (up to 4 years) | Phase B Visit 12 (up to 4 years) | Phase B Visit 13 (up to 4 years) | Phase B Visit 14 (up to 4 years) | Phase B Visit 15 (up to 4 years) | Phase B Visit 16 (up to 4 years) | Phase B Visit 17 (up to 4 years) | Phase B Visit 18 (up to 4 years) | Phase B Visit 19 (up to 4 years) | Phase B Visit 20 (up to 4 years) | Phase B Visit 21 (up to 4 years) | Phase B Visit 22 (up to 4 years) | Phase B Visit 23 (up to 4 years) | Phase B Visit 24 (up to 4 years) | Phase B EOT Visit (up to 4 years) | Survival Follow-Up 1 (up to 4 years) | Survival Follow-Up 2 (up to 4 years) | Survival Follow-Up 3 (up to 4 years) | Survival Follow-Up 4 (up to 4 years) | Survival Follow-Up 6 (up to 4 years) | |
| Bevacizumab: Phase B | 0.736 | 0.773 | 0.813 | 0.878 | 0.808 | 0.809 | 0.825 | 0.910 | 0.819 | 0.856 | 0.730 | 0.960 | 0.965 | 0.958 | 0.967 | 0.942 | 0.927 | 0.931 | 0.866 | 0.887 | 0.940 | 0.919 | 0.937 | 0.950 | 0.708 | 0.788 | 0.791 | 0.989 | 0.981 | 0.875 |
AQoL-8D provides a global utility score and comprised of 35 questions from which 8 dimensions (Independent Living, Life Satisfaction, Mental Health, Coping, Relationships, Self Worth, Pain, and Senses) are derived. Each of the 8 scales is calculated based on the answers to 3 questions. Each question is given an answer dependent utility score (0 [worst] to 1 [best]) and then these scores are combined using a multiplicative model to get the normalized scale score value, each scale ranging between 0.0 (representing death) and 1.0 (representing full health). (NCT01588990)
Timeframe: Baseline, every 8-9 weeks thereafter, EOT (30 days after disease progression [up to 4 years]), survival follow-up 12-weekly visits (up to 4 years) [Detailed time points are presented in the category titles]
| Intervention | units on a scale (Mean) | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phase A Baseline | Phase A Visit 2 (Weeks 8-9) | Phase A Visit 3 (Weeks 16-17) | Phase A Visit 4 (Weeks 24-25) | Phase A Visit 5 (Weeks 32-33) | Phase A Visit 6 (Weeks 40-41) | Phase A Visit 7 (Weeks 48-49) | Phase A Visit 8 (Weeks 56-57) | Phase A Visit 9 (Weeks 64-65) | Phase A Visit 10 (Weeks 72-73) | Phase A Visit 11 (Weeks 80-81) | Phase A Visit 12 (Weeks 88-89) | Phase A Visit 13 (Weeks 96-97) | Phase A Visit 14 (Weeks 104-105) | Phase A Visit 15 (Weeks 112-113) | Phase A Visit 16 (Weeks 120-121) | Phase A Visit 17 (Weeks 128-129) | Phase A Visit 18 (Weeks 136-137) | Phase A Visit 19 (Weeks 144-145) | Phase A Visit 20 (Weeks 152-153) | Phase A Visit 21 (Weeks 160-161) | Phase A Visit 22 (Weeks 168-169) | Phase A Visit 23 (Weeks 176-177) | Phase A EOT Visit (up to 4 years) | Survival Follow-Up 1 (up to 4 years) | Survival Follow-Up 2 (up to 4 years) | Survival Follow-Up 3 (up to 4 years) | Survival Follow-Up 4 (up to 4 years) | Survival Follow-Up 5 (up to 4 years) | Survival Follow-Up 6 (up to 4 years) | Survival Follow-Up 7 (up to 4 years) | |
| Bevacizumab: Phase A | 0.747 | 0.760 | 0.767 | 0.796 | 0.800 | 0.831 | 0.818 | 0.851 | 0.822 | 0.827 | 0.839 | 0.856 | 0.831 | 0.815 | 0.871 | 0.869 | 0.859 | 0.880 | 0.915 | 0.864 | 0.806 | 0.811 | 0.709 | 0.739 | 0.718 | 0.792 | 0.696 | 0.620 | 0.800 | 0.810 | 0.874 |
"EQ-5D is a standardized generic preference based health related quality of life instrument. It records how one's health is today and consists of a descriptive system. The descriptive system is comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Each dimension on the EQ-5D involves a 3-point response scale which indicates the level of impairment (level 1 = no problem; level 2 = some or moderate problem[s] and level 3 = unable, or extreme problems). Level of problem reported in each EQ-5D dimension determines a unique health state which is converted into a weighted health state index by applying scores from EQ-5D preference weights elicited from general population samples. This generates a unique description of the subjects' health status, which is valued between 0 (representing death) and 1 (representing perfect health). Higher the score, the better the quality of life." (NCT01588990)
Timeframe: Baseline, every 8-9 weeks thereafter, end of treatment (EOT) (30 days after disease progression [up to 4 years]), survival follow-up 12-weekly visits (up to 4 years) [Detailed time points are presented in the category titles]
| Intervention | units on a scale (Mean) | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phase A Baseline | Phase A Visit 2 (Weeks 8-9) | Phase A Visit 3 (Weeks 16-17) | Phase A Visit 4 (Weeks 24-25) | Phase A Visit 5 (Weeks 32-33) | Phase A Visit 6 (Weeks 40-41) | Phase A Visit 7 (Weeks 48-49) | Phase A Visit 8 (Weeks 56-57) | Phase A Visit 9 (Weeks 64-65) | Phase A Visit 10 (Weeks 72-73) | Phase A Visit 11 (Weeks 80-81) | Phase A Visit 12 (Weeks 88-89) | Phase A Visit 13 (Weeks 96-97) | Phase A Visit 14 (Weeks 104-105) | Phase A Visit 15 (Weeks 112-113) | Phase A Visit 16 (Weeks 120-121) | Phase A Visit 17 (Weeks 128-129) | Phase A Visit 18 (Weeks 136-137) | Phase A Visit 19 (Weeks 144-145) | Phase A Visit 20 (Weeks 152-153) | Phase A Visit 21 (Weeks 160-161) | Phase A Visit 22 (Weeks 168-169) | Phase A Visit 23 (Weeks 176-177) | Phase A EOT Visit (up to 4 years) | Survival Follow-Up 1 (up to 4 years) | Survival Follow-Up 2 (up to 4 years) | Survival Follow-Up 3 (up to 4 years) | Survival Follow-Up 4 (up to 4 years) | Survival Follow-Up 5 (up to 4 years) | Survival Follow-Up 6 (up to 4 years) | Survival Follow-Up 7 (up to 4 years) | |
| Bevacizumab: Phase A | 0.830 | 0.857 | 0.865 | 0.853 | 0.869 | 0.892 | 0.872 | 0.881 | 0.894 | 0.843 | 0.898 | 0.915 | 0.844 | 0.899 | 0.878 | 0.899 | 0.873 | 0.909 | 0.947 | 0.852 | 0.933 | 0.813 | 0.900 | 0.817 | 0.768 | 0.901 | 0.819 | 0.843 | 1.000 | 0.835 | 0.816 |
"EQ-5D is a standardized generic preference based health related quality of life instrument. It records how one's health is today and consists of a descriptive system. The descriptive system is comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Each dimension on the EQ-5D involves a 3-point response scale which indicates the level of impairment (level 1 = no problem; level 2 = some or moderate problem[s] and level 3 = unable, or extreme problems). Level of problem reported in each EQ-5D dimension determines a unique health state which is converted into a weighted health state index by applying scores from EQ-5D preference weights elicited from general population samples. This generates a unique description of the subjects' health status, which is valued between 0 (representing death) and 1 (representing perfect health). Higher the score, the better the quality of life." (NCT01588990)
Timeframe: Baseline, every 8-9 weeks thereafter, EOT (30 days after disease progression [up to 4 years]), survival follow-up 12-weekly visits (up to 4 years) [Detailed time points are presented in the category titles]
| Intervention | units on a scale (Mean) | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phase B Baseline | Phase B Visit 2 (up to 4 years) | Phase B Visit 3 (up to 4 years) | Phase B Visit 4 (up to 4 years) | Phase B Visit 5 (up to 4 years) | Phase B Visit 6 (up to 4 years) | Phase B Visit 7 (up to 4 years) | Phase B Visit 8 (up to 4 years) | Phase B Visit 9 (up to 4 years) | Phase B Visit 10 (up to 4 years) | Phase B Visit 11 (up to 4 years) | Phase B Visit 12 (up to 4 years) | Phase B Visit 13 (up to 4 years) | Phase B Visit 14 (up to 4 years) | Phase B Visit 15 (up to 4 years) | Phase B Visit 16 (up to 4 years) | Phase B Visit 17 (up to 4 years) | Phase B Visit 18 (up to 4 years) | Phase B Visit 19 (up to 4 years) | Phase B Visit 20 (up to 4 years) | Phase B Visit 21 (up to 4 years) | Phase B Visit 22 (up to 4 years) | Phase B Visit 23 (up to 4 years) | Phase B Visit 24 (up to 4 years) | Phase B EOT Visit (up to 4 years) | Survival Follow-Up 1 (up to 4 years) | Survival Follow-Up 2 (up to 4 years) | Survival Follow-Up 3 (up to 4 years) | Survival Follow-Up 4 (up to 4 years) | Survival Follow-Up 6 (up to 4 years) | |
| Bevacizumab: Phase B | 0.814 | 0.859 | 0.894 | 0.897 | 0.866 | 0.837 | 0.876 | 0.874 | 0.908 | 0.811 | 0.806 | 0.844 | 1.000 | 1.000 | 0.844 | 0.833 | 0.844 | 0.833 | 0.827 | 0.816 | 0.844 | 0.844 | 0.827 | 0.844 | 0.809 | 0.740 | 0.772 | 0.827 | 0.827 | 1.000 |
FACT-C is one part of the FACIT Measurement System, which comprehensively assesses the health-related QoL of cancer participants and participants with other chronic illnesses. It is composed of 27 items of the general version of the FACT-C as a general core QoL measure and has a disease-specific subscale containing 9 colorectal cancer-specific items. It consists of total 36 items, summarized to 5 subscales: physical well-being (7 items), functional well-being (7 items), social/family well-being (7 items); all 3 subscales range from 0 to 28, emotional well-being (6 items) range from 0 to 24, colorectal cancer subscale (9 items) range from 0 to 36; higher subscale score=better QoL. All single-item measures range from 0='Not at all' to 4='Very much'. Total possible score range: 0 to 144. High scale score represents a better QoL. (NCT01588990)
Timeframe: Baseline, every 8-9 weeks thereafter, EOT (30 days after disease progression [up to 4 years]), survival follow-up 12-weekly visits (up to 4 years) [Detailed time points are presented in the category titles]
| Intervention | units on a scale (Mean) | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phase B Baseline | Phase B Visit 2 (up to 4 years) | Phase B Visit 3 (up to 4 years) | Phase B Visit 4 (up to 4 years) | Phase B Visit 5 (up to 4 years) | Phase B Visit 6 (up to 4 years) | Phase B Visit 7 (up to 4 years) | Phase B Visit 8 (up to 4 years) | Phase B Visit 9 (up to 4 years) | Phase B Visit 10 (up to 4 years) | Phase B Visit 11 (up to 4 years) | Phase B Visit 12 (up to 4 years) | Phase B Visit 13 (up to 4 years) | Phase B Visit 14 (up to 4 years) | Phase B Visit 15 (up to 4 years) | Phase B Visit 16 (up to 4 years) | Phase B Visit 17 (up to 4 years) | Phase B Visit 18 (up to 4 years) | Phase B Visit 19 (up to 4 years) | Phase B Visit 20 (up to 4 years) | Phase B Visit 21 (up to 4 years) | Phase B Visit 22 (up to 4 years) | Phase B Visit 23 (up to 4 years) | Phase B Visit 24 (up to 4 years) | Phase B EOT Visit (up to 4 years) | Survival Follow-Up 1 (up to 4 years) | Survival Follow-Up 2 (up to 4 years) | Survival Follow-Up 3 (up to 4 years) | Survival Follow-Up 4 (up to 4 years) | Survival Follow-Up 6 (up to 4 years) | |
| Bevacizumab: Phase B | 103.47 | 108.71 | 108.19 | 114.89 | 110.60 | 111.28 | 114.78 | 120.39 | 108.08 | 110.50 | 109.33 | 125.00 | 119.00 | 117.00 | 126.00 | 123.00 | 127.00 | 126.00 | 127.00 | 126.00 | 123.00 | 124.00 | 126.00 | 130.00 | 101.67 | 98.72 | 102.50 | 126.33 | 125.00 | 124.67 |
FACT-C is one part of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, which comprehensively assesses the health-related QoL of cancer participants and participants with other chronic illnesses. It is composed of 27 items of the general version of the FACT-C as a general core QoL measure and has a disease-specific subscale containing 9 colorectal cancer-specific items. It consists of total 36 items, summarized to 5 subscales: physical well-being (7 items), functional well-being (7 items), social/family well-being (7 items); all 3 subscales range from 0 to 28, emotional well-being (6 items) range from 0 to 24, colorectal cancer subscale (9 items) range from 0 to 36; higher subscale score=better QoL. All single-item measures range from 0='Not at all' to 4='Very much'. Total possible score range: 0 to 144. High scale score represents a better QoL. (NCT01588990)
Timeframe: Baseline, every 8-9 weeks thereafter, EOT (30 days after disease progression [up to 4 years]), survival follow-up 12-weekly visits (up to 4 years) [Detailed time points are presented in the category titles]
| Intervention | units on a scale (Mean) | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phase A Baseline | Phase A Visit 2 (Weeks 8-9) | Phase A Visit 3 (Weeks 16-17) | Phase A Visit 4 (Weeks 24-25) | Phase A Visit 5 (Weeks 32-33) | Phase A Visit 6 (Weeks 40-41) | Phase A Visit 7 (Weeks 48-49) | Phase A Visit 8 (Weeks 56-57) | Phase A Visit 9 (Weeks 64-65) | Phase A Visit 10 (Weeks 72-73) | Phase A Visit 11 (Weeks 80-81) | Phase A Visit 12 (Weeks 88-89) | Phase A Visit 13 (Weeks 96-97) | Phase A Visit 14 (Weeks 104-105) | Phase A Visit 15 (Weeks 112-113) | Phase A Visit 16 (Weeks 120-121) | Phase A Visit 17 (Weeks 128-129) | Phase A Visit 18 (Weeks 136-137) | Phase A Visit 19 (Weeks 144-145) | Phase A Visit 20 (Weeks 152-153) | Phase A Visit 21 (Weeks 160-161) | Phase A Visit 22 (Weeks 168-169) | Phase A Visit 23 (Weeks 176-177) | Phase A EOT Visit (up to 4 years) | Survival Follow-Up 1 (up to 4 years) | Survival Follow-Up 2 (up to 4 years) | Survival Follow-Up 3 (up to 4 years) | Survival Follow-Up 4 (up to 4 years) | Survival Follow-Up 5 (up to 4 years) | Survival Follow-Up 6 (up to 4 years) | Survival Follow-Up 7 (up to 4 years) | |
| Bevacizumab: Phase A | 103.84 | 103.33 | 106.34 | 109.66 | 109.39 | 111.30 | 111.40 | 113.51 | 113.92 | 115.11 | 114.00 | 115.99 | 113.54 | 112.36 | 119.48 | 116.38 | 113.69 | 112.94 | 117.55 | 115.86 | 106.00 | 112.00 | 105.00 | 103.94 | 102.89 | 104.00 | 105.50 | 109.00 | 119.00 | 103.61 | 115.00 |
Percentage of participants with best overall response of confirmed complete response or partial response based on the investigator assessment of the response as per routine clinical practice was reported. The confirmation of response must be no less than 4 weeks after initial assessment. (NCT01588990)
Timeframe: Baseline up to disease progression, death or end of study (up to 4 years)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Complete response | Partial response | |
| Bevacizumab: Phase A and Phase B | 3.1 | 8.6 |
Percentage of participants with best overall response of confirmed complete response or partial response based on the investigator assessment of the response as per routine clinical practice was reported. The confirmation of response must be no less than 4 weeks after initial assessment. (NCT01588990)
Timeframe: Baseline up to disease progression, death or end of study (up to 4 years)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Complete response | Partial response | |
| Bevacizumab: Phase A | 3.1 | 8.6 |
Percentage of participants with best overall response of confirmed complete response or partial response based on the investigator assessment of the response as per routine clinical practice was reported. The confirmation of response must be no less than 4 weeks after initial assessment. (NCT01588990)
Timeframe: From the start of Phase B treatment to disease progression, death or end of study (up to 4 years)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Complete response | Partial response | |
| Bevacizumab: Phase B | 0 | 0 |
9 reviews available for fluorouracil and Innate Inflammatory Response
| Article | Year |
|---|---|
Inflamed actinic keratoses as a biomarker in repositioning of chemotherapeutics: a systematic review and meta-analysis.
Topics: Aged; Biomarkers; Drug Repositioning; Fluorouracil; Humans; Inflammation; Keratosis, Actinic; Middle | 2022 |
S-1 and 5-Fluorouracil-related adverse events in patients with advanced gastric cancer: A meta-analysis.
Topics: Fluorouracil; Humans; Hypokalemia; Hypophosphatemia; Inflammation; Stomach Neoplasms; Stomatitis | 2023 |
Impact of chemotherapy-induced enteric nervous system toxicity on gastrointestinal mucositis.
Topics: Animals; Antineoplastic Agents; Cisplatin; Enteric Nervous System; Fluorouracil; Gastrointestinal Di | 2020 |
Mediators of Inflammation in Topical Therapy of Skin Cancers.
Topics: Administration, Topical; Aminoquinolines; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineop | 2019 |
Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Cell Death; Colorectal Neoplas | 2014 |
Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Cell Death; Colorectal Neoplas | 2014 |
Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Cell Death; Colorectal Neoplas | 2014 |
Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Cell Death; Colorectal Neoplas | 2014 |
Keloids and Hypertrophic Scars: A Spectrum of Clinical Challenges.
Topics: Adjuvants, Immunologic; Aminoquinolines; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Anti | 2016 |
Mechanisms of inflammation in proliferative vitreoretinopathy: from bench to bedside.
Topics: Animals; Clinical Trials as Topic; Daunorubicin; Fluorouracil; Heparin, Low-Molecular-Weight; Humans | 2012 |
Potential mechanisms for chemotherapy-induced impairments in cognitive function.
Topics: Anemia; Animals; Antineoplastic Agents; Attention; Blood-Brain Barrier; Cognition Disorders; Cycloph | 2005 |
[Concomitant association of radiotherapy and chemotherapy in inflammatory breast cancer. Initial results of phase II trial].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality The | 1991 |
13 trials available for fluorouracil and Innate Inflammatory Response
| Article | Year |
|---|---|
The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab: A translational study [ASCENT].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomark | 2020 |
An Australian translational study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (Avastin™) [ASCENT].
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2013 |
Elevation in multiple serum inflammatory biomarkers predicts survival of pancreatic cancer patients with inoperable disease.
Topics: Adenocarcinoma; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C-Rea | 2014 |
Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes: Secondary Analysis of NSABP C-07/NRG Oncology Randomized Clinical Trial.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Class I Phosphatidylinositol 3-Kinases; | 2016 |
Health-related quality of life parameters as prognostic factors in a nonmetastatic breast cancer population: an international multicenter study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dis | 2004 |
A prospective evaluation of treatment with Selective Internal Radiation Therapy (SIR-spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biopsy; Colorectal Neoplasms; Disease-Free Survival; D | 2005 |
Nutrition intervention using an eicosapentaenoic acid (EPA)-containing supplement in patients with advanced colorectal cancer. Effects on nutritional and inflammatory status: a phase II trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Biomarkers; Body Composition; Campt | 2007 |
Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: ten-year results from the French Adjuvant Study Group GETIS 02 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosp | 2006 |
Effect of allopurinol on the toxicity of high-dose 5-fluorouracil administered by intermittent bolus injection.
Topics: Allopurinol; Clinical Trials as Topic; Drug Evaluation; Fluorouracil; Humans; Inflammation; Leukocyt | 1983 |
Treatment of inflamed hypertrophic scars using intralesional 5-FU.
Topics: Acne Vulgaris; Adult; Aged; Anti-Inflammatory Agents; Antimetabolites; Cicatrix; Female; Fluorouraci | 1999 |
Induction chemotherapy followed by concomitant chemoradiation therapy in advanced head and neck cancer: a phase II study for organ-sparing purposes evaluating feasibility, effectiveness and toxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; C | 2002 |
[Concomitant association of radiotherapy and chemotherapy in inflammatory breast cancer. Initial results of phase II trial].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality The | 1991 |
Cyclophosphamide versus 5-fluorouracil, doxorubicin, and mitomycin C (FAM') in the treatment of hormone-resistant metastatic carcinoma of the prostate: a preliminary report of a randomized trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; | 1985 |
116 other studies available for fluorouracil and Innate Inflammatory Response
| Article | Year |
|---|---|
Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
Topics: Animals; Biotinylation; Flow Cytometry; Fluorescence Resonance Energy Transfer; Green Fluorescent Pr | 2010 |
Melatonin derivatives combat with inflammation-related cancer by targeting the Main Culprit STAT3.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Cell Survival; Dose-Response Relation | 2021 |
Rupatadine protects the intestinal mucosa from injury by 5-flurouracil via modulation of inflammation, apoptosis and intestinal permeability.
Topics: Animals; Apoptosis; Aspartic Acid Proteases; Carboxymethylcellulose Sodium; Caspase 3; Cysteine; Flu | 2022 |
Losartan improves intestinal mucositis induced by 5-fluorouracil in mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antimetabolites, Antineoplastic; Cytokines; Female | 2021 |
Markers of tumor inflammation as prognostic factors for overall survival in patients with advanced pancreatic cancer receiving first-line FOLFIRINOX chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Fluorouracil; Humans; In | 2022 |
Protective role of casuarinin from Melastoma malabathricum against a mouse model of 5-fluorouracil-induced intestinal mucositis: Impact on inflammation and gut microbiota dysbiosis.
Topics: Animals; Disease Models, Animal; Dysbiosis; Fluorouracil; Gastrointestinal Diseases; Gastrointestina | 2022 |
Three important short-chain fatty acids (SCFAs) attenuate the inflammatory response induced by 5-FU and maintain the integrity of intestinal mucosal tight junction.
Topics: Animals; Beclin-1; Caco-2 Cells; Fatty Acids, Volatile; Fluorouracil; Humans; Inflammation; Interleu | 2022 |
Genetic variation in ST6GAL1 is a determinant of capecitabine and oxaliplatin induced hand-foot syndrome.
Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Colorectal Ne | 2022 |
The anticancer effects of cyanidin 3-O-glucoside combined with 5-fluorouracil on lung large-cell carcinoma in nude mice.
Topics: Animals; Anthocyanins; Carcinoma, Large Cell; Cell Line, Tumor; Fluorouracil; Glucosides; Inflammati | 2022 |
Dual roles of ANGPTL4 in multiple inflammatory responses in stomatitis mice.
Topics: Angiopoietin-Like Protein 4; Angiopoietins; Animals; Cytokines; Fluorouracil; Inflammation; Interleu | 2022 |
Protective Effect of
Topics: Antioxidants; Apocynaceae; Cytokines; Fluorouracil; Humans; Inflammation; Intestinal Mucosa; Latex; | 2023 |
Metformin ameliorates 5-fluorouracil-induced intestinalinjury by inhibiting cellular senescence, inflammation, and oxidative stress.
Topics: Animals; Cellular Senescence; Fluorouracil; Inflammation; Male; Metformin; Mice; Mice, Inbred BALB C | 2022 |
Short-Chain Fatty Acids Attenuate 5-Fluorouracil-Induced THP-1 Cell Inflammation through Inhibiting NF-κB/NLRP3 Signaling via Glycerolphospholipid and Sphingolipid Metabolism.
Topics: Anti-Inflammatory Agents; Fatty Acids, Volatile; Fluorouracil; Humans; Inflammasomes; Inflammation; | 2023 |
Polysaccharide Fraction from
Topics: Animals; Antimetabolites, Antineoplastic; Fluorouracil; Inflammation; Intestinal Mucosa; Mice; Mucos | 2023 |
Increasing Systemic Immune-inflammation Index During Treatment in Patients With Advanced Pancreatic Cancer is Associated With Poor Survival: A Retrospective, Multicenter, Cohort Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Fluorouracil; Humans; Inflammation; | 2023 |
Comparative evaluation of doxorubicin, cyclophosphamide, 5-fluorouracil, and cisplatin on cognitive dysfunction in rats: Delineating the role of inflammation of hippocampal neurons and hypothyroidism.
Topics: Animals; Cisplatin; Cognitive Dysfunction; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Hipp | 2023 |
Modulation of 5-fluorouracil activation of toll-like/MyD88/NF-κB/MAPK pathway by Saccharomyces boulardii CNCM I-745 probiotic.
Topics: Animals; Caco-2 Cells; Chemokine CXCL1; Cytokines; Fluorouracil; Humans; Ileum; Immunohistochemistry | 2020 |
Clinical significance of tumor-infiltrating lymphocytes and neutrophil-to-lymphocyte ratio in patients with stage III colon cancer who underwent surgery followed by FOLFOX chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Therapy; | 2019 |
Clerodane Diterpene Ameliorates Inflammatory Bowel Disease and Potentiates Cell Apoptosis of Colorectal Cancer.
Topics: Animals; Apoptosis; Azoxymethane; Biomarkers, Tumor; Caco-2 Cells; Cell Cycle; Cell Proliferation; C | 2019 |
Patchouli oil ameliorates 5-fluorouracil-induced intestinal mucositis in rats via protecting intestinal barrier and regulating water transport.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cytokines; Diarrhea; Dose-Response Relationship | 2020 |
Patchouli alcohol attenuates 5-fluorouracil-induced intestinal mucositis via TLR2/MyD88/NF-kB pathway and regulation of microbiota.
Topics: Animals; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Fluorouracil; Gastrointe | 2020 |
Use of STAT6 Phosphorylation Inhibitor and Trimethylglycine as New Adjuvant Therapies for 5-Fluorouracil in Colitis-Associated Tumorigenesis.
Topics: Adjuvants, Pharmaceutic; Animals; Apoptosis; beta Catenin; Cadherins; Carcinogenesis; Cell Adhesion | 2020 |
5-Fluorouracil in combination with deoxyribonucleosides and deoxyribose as possible therapeutic options for the Coronavirus, COVID-19 infection.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronaviru | 2020 |
Role of Rutin in 5-Fluorouracil-Induced Intestinal Mucositis: Prevention of Histological Damage and Reduction of Inflammation and Oxidative Stress.
Topics: Animals; Fluorouracil; Inflammation; Intestinal Diseases; Male; Mice; Mucositis; Oxidative Stress; R | 2020 |
Synergistic effects of Ficus Carica extract and extra virgin olive oil against oxidative injury, cytokine liberation, and inflammation mediated by 5-Fluorouracil in cardiac and renal tissues of male albino rats.
Topics: Animals; Antioxidants; Cytokines; Ficus; Fluorouracil; Inflammation; Male; Olive Oil; Oxidative Stre | 2021 |
Lactobacillus reuteri DSM 17938 and ATCC PTA 5289 ameliorates chemotherapy-induced oral mucositis.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Female; Fluorouracil; Inflammation; | 2020 |
Beneficial effect of oral administration of zinc sulfate on 5-fluorouracil-induced gastrointestinal mucositis in rats.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Disease Models, Animal; Female; Fluo | 2020 |
The Anti-Cancer Effects of a Zotarolimus and 5-Fluorouracil Combination Treatment on A549 Cell-Derived Tumors in BALB/c Nude Mice.
Topics: A549 Cells; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cytokines; ErbB Rece | 2021 |
Hepatoprotective Effect of Carboxymethyl Pachyman in Fluorouracil-Treated CT26-Bearing Mice.
Topics: Alanine Transaminase; Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Antioxidants; Apopto | 2017 |
Probiotic Bifidobacterium bifidum G9-1 attenuates 5-fluorouracil-induced intestinal mucositis in mice via suppression of dysbiosis-related secondary inflammatory responses.
Topics: Animals; Apoptosis; Bifidobacterium bifidum; Body Weight; Diarrhea; Dysbiosis; Fluorouracil; Inflamm | 2017 |
Chemotherapy-induced gastrointestinal toxicity is associated with changes in serum and urine metabolome and fecal microbiota in male Sprague-Dawley rats.
Topics: Animals; Antineoplastic Agents; Camptothecin; Feces; Fluorouracil; Gastrointestinal Diseases; Inflam | 2017 |
Alteration of Gut Microbiota and Inflammatory Cytokine/Chemokine Profiles in 5-Fluorouracil Induced Intestinal Mucositis.
Topics: Animals; Antigens, CD; Bacteria; Body Weight; Cadherins; Cell Adhesion Molecules; Chemokines; Colon; | 2017 |
Comparison between the efficacy of microneedling combined with 5-fluorouracil vs microneedling with tacrolimus in the treatment of vitiligo.
Topics: Administration, Cutaneous; Cosmetic Techniques; Dermatologic Agents; Female; Fluorouracil; Humans; H | 2018 |
Renal inhibition of miR-181a ameliorates 5-fluorouracil-induced mesangial cell apoptosis and nephrotoxicity.
Topics: Animals; Apoptosis; Base Sequence; Fluorouracil; HCT116 Cells; Humans; Inflammation; Inhibitor of Ap | 2018 |
Conjugated linoleic acid prevents damage caused by intestinal mucositis induced by 5-fluorouracil in an experimental model.
Topics: Animals; Bacterial Translocation; Body Weight; Chemokines; Disease Models, Animal; Feeding Behavior; | 2018 |
Folate-producing lactic acid bacteria reduce inflammation in mice with induced intestinal mucositis.
Topics: Animals; Caco-2 Cells; Cytokines; Diarrhea; Fluorouracil; Folic Acid; Humans; Inflammation; Intestin | 2018 |
Effects of Onchung-eum, an Herbal Prescription, on 5-Fluorouracil-Induced Oral Mucositis.
Topics: Animals; Cell Death; Cell Survival; Cytokines; Fluorouracil; Herbal Medicine; Humans; Inflammation; | 2018 |
Gut microbiome modulation during treatment of mucositis with the dairy bacterium Lactococcus lactis and recombinant strain secreting human antimicrobial PAP.
Topics: Animals; Anti-Infective Agents; Biodiversity; Feces; Female; Fluorouracil; Gastrointestinal Microbio | 2018 |
Topical kinase inhibitors induce regression of cutaneous squamous cell carcinoma.
Topics: Administration, Topical; Animals; Carcinoma, Squamous Cell; Dasatinib; Fluorouracil; Humans; Imidazo | 2019 |
Impact of 5 fluorouracil chemotherapy on gut inflammation, functional parameters, and gut microbiota.
Topics: Animals; Azoxymethane; Colitis; Colon; Colonic Neoplasms; Colorectal Neoplasms; Dextran Sulfate; Dis | 2019 |
Amifostine reduces inflammation and protects against 5-fluorouracil-induced oral mucositis and hyposalivation.
Topics: Amifostine; Animals; Cricetinae; Disease Models, Animal; Fluorouracil; Inflammation; Male; Protectiv | 2019 |
Chemotherapy-induced oral mucositis is associated with detrimental bacterial dysbiosis.
Topics: Antineoplastic Agents; Bacteria; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Dysb | 2019 |
Dysregulation in myelination mediated by persistent neuroinflammation: possible mechanisms in chemotherapy-related cognitive impairment.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cognition Disorders; Corpus Callosum; Cyclo | 2014 |
The potential contribution of tumour-related factors to the development of FOLFOX-induced sinusoidal obstruction syndrome.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Chemical and Drug Induced | 2013 |
Experimental study on sustained-release 5-Fluorouracil implantation in canine peritoneum and para-aortic abdominalis.
Topics: Animals; Antimetabolites, Antineoplastic; Dogs; Drug Implants; Edema; Fluorouracil; Humans; Inflamma | 2014 |
Dietary quercetin reduces chemotherapy-induced fatigue in mice.
Topics: Anemia; Animals; Antimetabolites, Antineoplastic; Chemokine CCL2; Dietary Supplements; Disease Model | 2014 |
Effect of mitomycin, bevacizumab, and 5-Fluorouracil to inhibit urethral fibrosis in a rabbit model.
Topics: Animals; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Bevacizumab; Collagen; Disease | 2014 |
The assessment of general well-being using spontaneous burrowing behaviour in a short-term model of chemotherapy-induced mucositis in the rat.
Topics: Animal Welfare; Animals; Disease Models, Animal; Drug Therapy; Fluorouracil; Inflammation; Injection | 2015 |
Systemic inflammation, as measured by the neutrophil/lymphocyte ratio, may have differential prognostic impact before and during treatment with fluorouracil, irinotecan and bevacizumab in metastatic colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizuma | 2014 |
The impact of inflammatory lipid mediators on colon cancer-initiating cells.
Topics: Animals; Caco-2 Cells; Cell Line, Tumor; Colonic Neoplasms; Dinoprostone; Disease Progression; Drug | 2015 |
Omega-3 fatty acid is a potential preventive agent for recurrent colon cancer.
Topics: Animals; Anticarcinogenic Agents; beta Catenin; Biomarkers, Tumor; Cell Line, Tumor; Colon; Colonic | 2014 |
Role of genetic polymorphisms in NFKB-mediated inflammatory pathways in response to primary chemoradiation therapy for rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Chemoradiotherapy; Cyclooxygenase 1; Cyclooxygenase 2; | 2014 |
S-nitrosoglutathione accelerates recovery from 5-fluorouracil-induced oral mucositis.
Topics: Administration, Topical; Animals; Cricetinae; Disease Models, Animal; Fluorouracil; Gene Expression | 2014 |
Regulatory role of Lactobacillus acidophilus on inflammation and gastric dysmotility in intestinal mucositis induced by 5-fluorouracil in mice.
Topics: Animals; Antimetabolites, Antineoplastic; Cytokines; Fluorouracil; Gastric Emptying; Gastrointestina | 2015 |
An Immune-Modulating Diet in Combination with Chemotherapy Prevents Cancer Cachexia by Attenuating Systemic Inflammation in Colon 26 Tumor-Bearing Mice.
Topics: Animals; Antineoplastic Agents; Blood Glucose; Cachexia; Cell Line, Tumor; Colon; Colonic Neoplasms; | 2015 |
Effect of low-level laser therapy as an adjuvant in the treatment of periodontitis induced in rats subjected to 5-fluorouracil chemotherapy.
Topics: Alveolar Bone Loss; Animals; Bacteria; Caspase 3; Combined Modality Therapy; Dental Scaling; Dinopro | 2016 |
Role of NADPH oxidase 1 (NOX1) in gut inflammation.
Topics: Animals; Fluorouracil; Humans; Inflammation; Intestines; NADH, NADPH Oxidoreductases; NADPH Oxidase | 2016 |
Role of Hematopoietic Stem Cells in Inflammation of the Pancreas during Diabetes Mellitus.
Topics: Animals; Bone Marrow Cells; Cell Differentiation; Cell- and Tissue-Based Therapy; Diabetes Mellitus, | 2016 |
Administration of probiotic mixture DM#1 ameliorated 5-fluorouracil-induced intestinal mucositis and dysbiosis in rats.
Topics: Animals; Cytokines; Dysbiosis; Fluorouracil; Gastrointestinal Microbiome; Ileum; Inflammation; Inter | 2017 |
Alleviation of 5-fluorouracil-induced intestinal mucositis in rats by vitamin E via targeting oxidative stress and inflammatory markers.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Biomarkers; Cyclooxygenase 2; Fluorouracil; Inflamm | 2016 |
Analysis of molecular mechanisms of 5-fluorouracil-induced steatosis and inflammation in vitro and in mice.
Topics: Acyl-CoA Oxidase; Animals; Antimetabolites, Antineoplastic; Blotting, Western; Cells, Cultured; Dise | 2017 |
Cetuximab strongly enhances immune cell infiltration into liver metastatic sites in colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2017 |
Serum levels of NFkappaB and pro-inflammatory cytokines following administration of mucotoxic drugs.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cytokines; Epithelium; Female; Fluorouracil; Gastroint | 2008 |
In vitro / in vivo evaluation of NCDS-micro-fabricated biodegradable implant.
Topics: Absorbable Implants; Animals; Antimetabolites, Antineoplastic; Chemistry, Pharmaceutical; Delayed-Ac | 2010 |
Novel targeted therapies in inflammatory breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug | 2010 |
Overcoming radiation resistance in inflammatory breast cancer.
Topics: Breast Neoplasms; Capecitabine; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Female; | 2010 |
Essential role for focal adhesion kinase in regulating stress hematopoiesis.
Topics: Actins; Acute Disease; Animals; Bone Marrow Cells; Cell Movement; Cell Proliferation; Cell Survival; | 2010 |
Dietary emu oil supplementation suppresses 5-fluorouracil chemotherapy-induced inflammation, osteoclast formation, and bone loss.
Topics: Animals; Antimetabolites, Antineoplastic; Bone and Bones; Bone Resorption; Caseins; Diet; Dietary Fa | 2012 |
The effects of 5-fluorouracil on flexor tendon healing by using a biodegradable gelatin, slow releasing system: experimental study in a hen model.
Topics: Absorbable Implants; Animals; Antimetabolites, Antineoplastic; Casts, Surgical; Chickens; Delayed-Ac | 2013 |
Effects of 5-fluorouracil chemotherapy on fatigue: role of MCP-1.
Topics: Anemia; Animals; Antimetabolites, Antineoplastic; Chemokine CCL2; Dose-Response Relationship, Drug; | 2013 |
NLRP1 inflammasome activation induces pyroptosis of hematopoietic progenitor cells.
Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Apoptosis Regulatory Proteins; CARD Signal | 2012 |
Raltitrexed treatment promotes systemic inflammatory reaction in patients with colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2002 |
Simultaneous onset of acute inflammatory response, sepsis-like symptoms and intestinal mucosal injury after cancer chemotherapy.
Topics: Animals; Antineoplastic Agents; Bacteria; Bacterial Infections; Bacterial Translocation; Digestive S | 2003 |
STUDIES ON THE LYMPHOCYTE RESPONSE TO INFLAMMATION.
Topics: Agranulocytosis; Aminopterin; Animals; Azaguanine; Biopsy; Chloramphenicol; Connective Tissue; Cyclo | 1964 |
INHIBITION OF THE LYMPHOCYTE RESPONSE TO INFLAMMATION WITH ANTIMETABOLITES.
Topics: Aminopterin; Antimetabolites; Azaguanine; Chloramphenicol; Connective Tissue; Cyclophosphamide; Dact | 1964 |
Combined 5-fluorouracil/systemic interferon-beta gene therapy results in long-term survival in mice with established colorectal liver metastases.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Colorectal Neop | 2004 |
Concurrent chemoradiotherapy with pirarubicin and 5-fluorouracil for resectable oral and maxillary carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Combined Mo | 2004 |
Long-term results of combined-modality therapy for inflammatory breast carcinoma.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical | 2004 |
Pre-treatment with insulin-like growth factor-I partially ameliorates 5-fluorouracil-induced intestinal mucositis in rats.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Body Weight; Bromodeoxyuridine; Cell Proliferat | 2005 |
Inflammatory breast cancer in a male.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Cyclophospha | 2005 |
Effective dose of 5-fluorouracil for myringotomy in rats.
Topics: Animals; Antimetabolites; Dose-Response Relationship, Drug; Fibrosis; Fluorouracil; Inflammation; Mi | 2005 |
Docetaxel administered during pregnancy for inflammatory breast carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide | 2006 |
The presence of a systemic inflammatory response predicts poorer survival in patients receiving adjuvant 5-FU chemotherapy following potentially curative resection for colorectal cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; C-Reactive Protein; Chemotherapy, Adjuvant; C | 2006 |
Hematopoietic cells from gadd45a-deficient and gadd45b-deficient mice exhibit impaired stress responses to acute stimulation with cytokines, myeloablation and inflammation.
Topics: Animals; Antigens, Differentiation; Apoptosis; Blotting, Northern; Bone Marrow Cells; Caseins; Cell | 2006 |
[A case of inflammatory breast cancer achieving pathological complete response by primary systemic therapy with CEF (cyclophosphamide, epirubicin, 5-fluorouracil) followed by docetaxel].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Combine | 2007 |
[Comparison of the suppressing capecitabine and 5-fluorouracil effects on the pronounce of inflammatory cells score in the induction of episcleral fibrosis after trabeculectomy].
Topics: Animals; Capecitabine; Deoxycytidine; Fibrosis; Fluorouracil; Glaucoma; Inflammation; Rabbits; Scler | 2007 |
Lyprinol only partially improves indicators of small intestinal integrity in a rat model of 5-fluorouracil-induced mucositis.
Topics: Animals; Antimetabolites, Antineoplastic; Breath Tests; Disease Models, Animal; Dose-Response Relati | 2008 |
Fluorine-18-labeled 5-fluorouracil is a useful radiotracer for differentiation of malignant tumors from inflammatory lesions.
Topics: Animals; Colonic Neoplasms; Diagnosis, Differential; Female; Fluorine Radioisotopes; Fluorouracil; I | 2008 |
Capecitabine induced inflammation of actinic keratoses.
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluoro | 2007 |
Decreased immunosuppression associated with antitumor activity of 5-deoxy-5-fluorouridine compared to 5-fluorouracil and 5-fluorouridine.
Topics: Animals; Antineoplastic Agents; Cell Survival; Female; Floxuridine; Fluorouracil; Immunosuppression | 1983 |
New possibilities of cytostatic drug testing on patient tumor cells by flow cytometry.
Topics: Antineoplastic Agents; Ascitic Fluid; Cell Survival; Cells, Cultured; Cisplatin; Cyclophosphamide; D | 1984 |
Fine-needle aspiration cytology in locally advanced breast adenocarcinoma: a case with complete response to preoperative chemotherapy in association with granulomatous inflammatory reaction.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplas | 1994 |
Mediastinal infusion of epirubicin and 5-fluorouracil. A complication of totally implantable central venous systems. Report of a case.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Catheterization, Central Venous; Catheters, In | 1996 |
Recurrent inflammation in a site of previous necrotising fasciitis during intravenous CMF chemotherapy.
Topics: Abdomen; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cicatrix; Cyclophosphamid | 1999 |
[Evaluation of hepatic toxicity following high-dose 5-FU arterial infusion chemotherapy: analysis of 42 cases of colorectal liver metastases].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Atrophy; Chemical and Drug Induced Liver Injury; Color | 2000 |
Healing of experimental colonic anastomoses: effects of combined preoperative high-dose radiotherapy and intraperitoneal 5-fluorouracil.
Topics: Anastomosis, Surgical; Animals; Antimetabolites, Antineoplastic; Body Weight; Colon; Colonic Disease | 2001 |
[Toxicological studies of bleomycin ointment. Subacute and chronic toxicity in rabbits (author's transl)].
Topics: Administration, Topical; Animals; Bleomycin; Blood Cell Count; Fluorouracil; Inflammation; Male; Oin | 1975 |
The acute effects of various cytotoxic compounds injected into the prostate glands of dogs.
Topics: Animals; Antineoplastic Agents; Dactinomycin; Dogs; Ethoglucid; Fluorouracil; Inflammation; Injectio | 1978 |
Inflammatory breast cancer: integration of irradiation, surgery, and chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combi | 1992 |
Multifocal inflammatory leukoencephalopathy with 5-fluorouracil and levamisole.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Ataxia; Biopsy; Brain; Chemoth | 1992 |
Trabeculectomy with 5-fluorouracil for adult inflammatory glaucoma.
Topics: Adult; Aged; Female; Fluorometholone; Fluorouracil; Follow-Up Studies; Glaucoma; Humans; Inflammatio | 1990 |
Adjusting the dose of 5-fluorouracil after filtration surgery to minimize side effects.
Topics: Adult; Aged; Female; Fluorouracil; Glaucoma; Humans; Inflammation; Intraocular Pressure; Iris; Male; | 1987 |
Leucovorin calcium enhancement of mucositis after continuous infusion fluorouracil and short infusion cisplatin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Fluor | 1989 |
Chemical cholecystitis associated with hepatic arterial chemotherapy delivered by a permanently implanted pump.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Arteritis; Carcinoma, Hepatocellular; Cholecystitis; Ch | 1985 |
Beneficial response of local immunotherapy with Propionibacterium granulosum KP-45 in combined treatment of inflammatory breast carcinoma.
Topics: Adult; Aged; Antigens, Bacterial; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1988 |
Studies of eicosanoid production in the air pouch model of synovial inflammation.
Topics: 6-Ketoprostaglandin F1 alpha; Air; Animals; Carrageenan; Colchicine; Dinoprostone; Disease Models, A | 1986 |
Inflammatory breast carcinoma. Effective multimodal approach.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Co | 1987 |
Primary chemotherapy in the treatment of inflammatory breast carcinoma: a study of 230 cases from the Institut Gustave-Roussy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; C | 1986 |
Phase II trial of high-dose continuous infusion 5-fluorouracil with allopurinol modulation in colon cancer.
Topics: Adult; Aged; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Ev | 1986 |
[The effect of various antibiotics, corticosteroids and cytostatic preparations on the morphology of experimental aspergillosis].
Topics: Animals; Antineoplastic Agents; Aspergillosis; Aspergillus fumigatus; Brain; Chlortetracycline; Cycl | 1972 |
Letter: Multiple actinic keratoses of the forehead.
Topics: Administration, Topical; Dermatomyositis; Fluorouracil; Humans; Inflammation; Keratosis; Male; Middl | 1973 |
Proceedings: Use of 5 fluorouracil in the topical therapy of skin cancer: a review of 157 patients.
Topics: Administration, Topical; Adult; Aged; Carcinoma in Situ; Carcinoma, Basal Cell; Carcinoma, Basosquam | 1972 |
Studies on the antiphlogistic activity of cytostatics.
Topics: Animals; Anti-Inflammatory Agents; Antimetabolites; Carrageenan; Chloramphenicol; Cyclophosphamide; | 1972 |
Topical chemotherapy of advanced cutaneous malignancy with 5-Fluorouracil creme.
Topics: Aged; Carcinoma; Carcinoma, Basal Cell; Carcinoma, Basosquamous; Carcinoma, Squamous Cell; Esthetics | 1971 |
Inflammation of actinic keratosis secondary to systemic 5-fluorouracil.
Topics: Aged; Female; Fluorouracil; Humans; Inflammation; Keratosis | 1968 |
Inflammation of actinic keratoses due to systemic fluorouracil therapy.
Topics: Aged; Breast Neoplasms; Female; Fluorouracil; Humans; Inflammation; Keratosis | 1969 |